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ABSTRACT 
A major translational challenge in the fields of therapeutic angiogenesis 
and tissue engineering is the ability to form functional networks of blood vessels. 
Cell-based strategies to promote neovascularization have led to the consensus 
that co-delivery of endothelial cells (ECs) with a supporting stromal cell type is 
the most effective approach. However, the choice of stromal cells has varied 
across studies, and their impact on the functional qualities of the capillaries 
produced has not been examined.  
Our lab has developed methods to form interconnected networks of 
pericyte-invested capillaries both in vitro in a 3D cell culture model and in vivo. 
However, if the engineered vessels contain ECs that are misaligned or contain 
wide junctional gaps, they may function improperly and behave more like the 
pathologic vessels that nourish tumors. The purpose of this thesis was to 
determine if stromal cells of different origins yield capillaries with different 
functional properties, in complementary in vitro and in vivo models. 
In vitro, a fluorescent dextran tracer was used to visualize and quantify 
transport across the endothelium. In EC-fibroblast co-cultures, the dextran tracer 
penetrated through the vessel wall and permeability was high through the first 5 
days of culture, indicative of vessel immaturity. Beyond day 5, tracer 
accumulated at the vessel periphery, with very little transported across the 
xii 
endothelium. When ECs were co-cultured with bone marrow-derived 
mesenchymal stem cells (MSCs) or adipose-derived stem cells (AdSCs), tighter 
control of permeability was achieved.  
In vivo, all conditions yielded new vessels that inosculated with mouse 
dorsal vasculature and perfused the implant, but there were significant functional 
differences, depending on the identity of the co-delivered stromal cells. EC alone 
and EC-fibroblast implants yielded immature capillary beds characterized by high 
levels of erythrocyte pooling in the surrounding matrix, while EC-MSC and EC-
AdSC implants produced more mature capillaries characterized by less 
extravascular leakage and expression of mature pericyte markers. Injection of 
dextran tracer into the circulation also showed that EC-MSC and EC-AdSC 
implants formed vasculature with more tightly regulated permeability. These 
results suggest that the identity of the stromal cells is key to controlling the 
functional properties of engineered capillary networks. 
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CHAPTER 1 
Introduction 
 
1.1 Motivation and Background of the Thesis 
 
Cardiovascular diseases are the leading cause of death in the Western 
world, often requiring vascular reconstruction or other therapeutic intervention.(1) 
Because autologous donor vessels are not always a viable option for the 
treatment of these ischemic diseases, particularly for small diameter vessels 
such as capillaries, tissue engineered blood vessels are a highly studied area.(2) 
The process of engineering new vessels has been approached in two ways. New 
blood vessels can be engineered outside of the body and then implanted and 
ultimately anastamose with existing host vasculature.(3) Alternatively, treatment 
to encourage blood vessel growth can be administered (either as implanted 
cells(4, 5), or soluble factors(6)), resulting in the sprouting and growth of new 
vessels in situ.  
The process of new capillaries sprouting and growing out of existing blood 
vessels, known as angiogenesis, is a complex process that is difficult to 
control.(7) Several pro-angiogenic regulators, including vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth 
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factor (PDGF), hepatocyte growth factor (HGF), and transforming growth factor-β 
(TGF-β), have previously been used to encourage capillary growth, both directly 
in the body, as well as in vitro.(8, 9) However, stimulating vessel formation with 
these proangiogenic molecules has caused uncontrolled growth and led to an 
abnormal cellular structure and function, as well as edema, hypertension, and 
septic shock in vivo.(10) 
As an alternative to the direct administration of exogenous soluble factors, 
our lab has successfully developed a robust method for growing interconnected 
networks of pericyte-invested capillary blood vessels by distributing endothelial 
cells and supporting stromal cells in a 3D fibrin matrix.(11) These vessels are 
able to anastamose with host vasculature following implantation in order to 
restore blood flow, deliver nutrients, and remove metabolic waste products in 
previously ischemic tissues. However, these blood vessels have not been tested 
to determine their functionality as physiologically healthy vessel networks. If 
these new capillaries have grown too quickly, or with an imbalance of the 
previously described growth factors, they may contain endothelial cells that are 
misaligned, stacked, or contain wide junctional gaps.(12) Other differences in 
functionality or appearance may also exist which could hinder proper function in 
the body as well. 
Multiple cell types have previously been shown to function as pericytes 
and promote capillary morphogenesis, specifically mesenchymal bone marrow-
derived stem cells (MSCs)(11), fibroblasts(13), adipose-derived stem cells 
(AdSCs) (14), and vascular smooth muscle cells(15). Capillaries grown with each 
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cell type have been shown to grow into mature sprouts with stalks, tip cells, and 
hollow lumens.(11, 16) While each of these cell types promotes capillary sprout 
formation, it is still unknown whether each is capable of regulating vessel 
permeability in the same manner as healthy, mature vessels.(13) Previous work 
shows that these different cell types instruct endothelial cells to use different 
proteolytic mechanisms to remodel and promote capillary sprouting via different 
proteolytic enzymes, although the ultimate morphological outcomes appear to be 
similar.(17) More specifically, fibroblast-mediated capillary morphogenesis was 
only shown to be knocked down by the inhibition of both soluble MMPs and 
plasmin, thus allowing our lab to conclude that multiple proteases mediate this 
sprouting phenomenon.(14, 17) When MSCs were used in the place of 
fibroblasts, inhibition of soluble MMPs resulted in total knockdown of sprouting. 
Plasmin inhibition had no effect on sprouting in this system, thus allowing us to 
conclude that EC-MSC co-cultures utilize only soluble MMPs for sprouting. 
Specifically, MT1-MMP was found to mediate capillary morphogenesis. Adipose-
derived stem cells promote angiogenesis via the plasminogen activator-plasmin 
axis. Based on these cues from previous work, the purpose of the experiments 
conducted in the scope of this dissertation was to evaluate the functional 
differences of engineered blood vessels formed in the presence of various 
stromal cell types.  
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1.2 Description of Engineered Blood Vessels 
 
 Engineered tissues require vascularization in order to overcome 
diffusional barriers and induce healthy tissue growth and maintenance.(18, 19) 
Blood vessels bring nutrients, other molecules such as growth factors and 
cytokines, as well as erythrocytes and various types of immune cells to tissues in 
different areas throughout the body. A healthy vascular network branches in a 
hierarchy of blood vessels, starting with arteries and veins to act as pipelines to 
transport large volumes of blood, and working downward in size to arterioles, 
venules, and finally, capillaries.(20) Capillaries maintain a large surface area 
within a tissue, allowing for oxygen diffusion and transport from the vessel into 
the surrounding tissue. These are the most numerous vessel type in the human 
body.(21, 22) 
 In order to grow engineered tissues in a laboratory setting, multiple cell 
types must work in tandem with extracellular matrix molecules to create a 
specific tissue.(23) Blood vessels must vascularize the new tissue at its outset in 
order to produce a three-dimensional product. The limits of diffusion, known to be 
approximately 200 microns in tissues such as muscle, have previously put a limit 
on the achievable thickness of engineered tissues.(24) Early successes in the 
field of tissue engineering have been with thin tissues (e.g., skin), relatively 
avascular tissues (e.g., cartilage), and hollow organs (e.g., bladder), where a 
dense vasculature is not necessary for tissue function and maintenance.(25-27)  
 All blood vessels are comprised of endothelial cells and some type of 
mural cells.(28) Endothelial cells line the inner side of a blood vessel, coming into 
5 
contact with the flowing blood and preventing clot formation.(29) Mural cells 
reside on the outer face of a blood vessel, embedded in the extracellular matrix. 
These cells work together with the endothelial cells to provide stabilization cues 
to the endothelial tubules.(29) Various different stromal cells work in concert with 
the endothelial cells to promote different types of blood vessels in different parts 
of the body. Capillary endothelial tubules are sparsely covered with pericytes, 
mural cells that provide stabilization cues to the endothelial cells to allow for 
proper nutrient and gas exchange to the surrounding tissue.(30) Capillaries can 
have endothelial layers that are continuous, fenestrated, or discontinuous in 
various places such as muscle, kidney, and liver.(31) Capillaries that comprise 
the blood-brain barrier are further specialized to include tight junctions that limit 
molecule permeability to protect the brain. In all capillaries, a layer of basement 
membrane (a specialized ECM) lies underneath the endothelial cells and 
provides a substrate for pericyte attachment.(32, 33) Pericytes are also a 
mechanism to prevent healthy blood vessels in properly nourished tissues from 
further sprouting. (34) 
Arterioles, which have a much lower permeability than capillaries, are 
surrounded by a circumferentially arranged layer of smooth muscle cells, whose 
contractile properties allow for alteration of diameter for blood pressure 
control.(35) Postcapillary venules are the main area of macromolecular and 
cellular exchange into the blood.(36) Larger blood vessels contain additional 
layers of extracellular matrix and elastic lamina, due to their main function as 
tubes to carry blood, rather than allowing exchange of materials with the 
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surrounding tissue. An internal elastic lamina surrounds the endothelial cell tube, 
and an additional external elastic lamina provides a barrier to the outer 
extracellular matrix and connective tissue.(10)  
Several methods can be employed to solve the challenge of creating 
tissue engineered blood vessels. One option is to create a vascular network in 
vitro that can then be implanted and anastamose with the host network. An 
alternative to this is to deliver a precise cocktail of pro-angiogenic factors to 
spatially and temporally control host vasculature recruitment. One limitation of 
this approach is the fact that the half-life of most pro-angiogenic protein factors is 
often extremely short, which can result in limited bioactivity.(37, 38) Also, the 
physiologic system is very complex and constantly changing, which is difficult to 
recapitulate. An alternative to this approach is to deliver a combination of 
appropriate cell types that can produce a physiologically relevant cocktail of 
these pro-angiogenic factors.(39) This approach is strengthened by the fact that 
the cells can respond to local changes in the environment and consequently alter 
the cues produced to induce vasculature sprouting.(40) Our lab has explored the 
utility of this second approach by delivering ECs with a variety of different stromal 
cell types to induce capillary sprouting, both in vitro and in vivo.  
1.3 Introduction to Capillary Functionality 
 
Capillary functionality in physiologically healthy tissues is phenotypically 
different than that seen in tumor physiology or in other pathological cases. Tumor 
physiology induces abnormal blood vessel growth due in part to the speed of 
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vessel formation and abnormal variations of pro-angiogenic cues released by the 
tumor itself.(41) Tumor vasculature has many phenotypic hallmarks, including 
irregular vessel diameters, abnormal branching patterns, and a disruption of the 
hierarchical differentiation structure into arteries, arterioles, capillaries, post-
capillary venules, and veins.(42) These blood vessels are also known to have 
defective wall structures, and may contain wide junctional gaps between 
endothelial cells.(43) Levels of VE-cadherin are downregulated in cancer 
vasculature, indicating a lack of proper EC-EC cadherins junctions that control 
permeability between neighboring cells.(44) There is also often an incomplete 
basement membrane, which can encourage further angiogenic sprouting by 
failing to block the interstitial collagens that stimulate sprouting.(45) Tumor 
vasculature is also characterized by an abnormal pericyte coat, which implies a 
lack of stabilization within the vascular network, and can result in constant 
remodeling and continuous growth of the network to nourish the growing tumor 
structure.(46, 47) Previous work in other labs has also shown a faster than 
normal rate of endothelial cell turnover, as well as higher luminal resistance, and 
overexpression of integrins such as α5β1. (48)  
In most previous studies, the sole assessment of blood vessel functionality 
in engineered tissue applications has been the histological observation of vessel-
like structures that contain lumens filled with host red blood cells.(49) However, 
there are many additional features of a blood vessel that are necessary for 
proper function. The vessel must respond to vasoactive stimuli in order to 
maintain proper blood pressure throughout the body.(50) Surrounding tissue 
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must be sufficiently oxygenated in order to avoid the development of a hypoxic 
environment.(24, 51) Newly sprouting blood vessels must lay down a basement 
membrane to provide a separation barrier between the endothelial cells and their 
collagenous extracellular environment (to produce stabilized vessels and 
discourage further sprouting) and to produce extracellular matrix proteins that 
provide mechanical support and stability to the area.(52, 53) Vascular 
permeability must be able to be tightly controlled as well. In arteries and 
arterioles, as well as veins and venules, permeability levels should be extremely 
low, as these types of vessels primarily function as conduits for convective blood 
transport throughout the body.(54) At the capillary level, the permeability 
capabilities are drastically different. Red blood cells should not be able to escape 
between neighboring ECs, but many growth factors, small gas molecules, and 
other small molecules should be able to reach the external tissue.(55)  
1.4 Overarching Hypothesis 
 
We hypothesize that the use of different stromal cell types will produce 
capillary networks with varying levels of functionality and rates of maturity. 
1.5 Specific Aims 
 
1. Quantitatively determine the kinetics of capillary functionality by 
developing an in vitro model of inverse permeability. Our hypothesis is that 
the engineered capillaries will be initially leaky as they are developing into 
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interconnected networks, but will mature into healthy networks of aligned, 
pericyte-stabilized endothelial cells with selective permeability that mimics that of 
physiologically healthy capillaries. 
2. Compare the performances of 3 different cell types (fibroblasts, MSCs, 
and AdSCs) as a functional pericyte coat for mature development and 
stabilization of a capillary network in vitro. Our hypothesis is that the use of 
varying stromal cell types will enable capillary networks to mature at varying 
rates and with different functionalities due to the formation of stabilizing cell-cell 
junctions and pericytic associations.  
3. Quantitatively determine the kinetics of capillary function with an in vivo 
mouse model of subcutaneous wound healing. We hypothesize that the 
kinetics of capillary morphogenesis and the achievement of functional, healthy 
vessels in vivo will mimic those of our in vitro model. 
1.6 Translational Potential 
 
 Treatment of ischemic diseases in the clinic is a rising medical concern. 
Many patients are unable to withstand the highly invasive surgical treatments that 
are the current standard of care. Thus, new treatments are needed.(56) Ischemic 
diseases represent the leading cause of death in the western world, with heart 
disease, as well as other circulatory and peripheral vascular diseases as the 
leading players.(1) Commonly, bypass grafts are needed to circumvent 
blockages and restore blood flow to areas with high metabolic demands, such as 
the heart. The biggest challenge here is to find a suitable graft site where no 
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blockage currently exists. Often, patients who present with blockages in the 
vessels surrounding the heart also have blockages in vessels throughout the 
body, thus making it difficult to find a suitable graft.(57, 58)  
 Other peripheral ischemic diseases could also benefit from therapeutic 
angiogenesis or treatment with engineered capillary networks. Peripheral 
vascular diseases, such as diabetic retinopathy or ischemic neuropathy, could 
also potentially be treated by promoting increased angiogenic sprouting in areas 
of ischemia.(59, 60) Injection to the site of ischemia with pro-angiogenic growth 
factors, cytokines, or cells that are able to secrete these factors could be 
effective methods to induce vascularization where it is lacking.(61)  
 For effective translation of tissue engineered capillary networks to the 
clinic, physiological parameters of these new vessels need to be evaluated. 
Delivery of a cocktail containing a variety of pro-angiogenics (or specific cell 
types which are able to produce these pro-angiogenic signaling molecules) can 
result in broad variations in the phenotypes of the resulting blood vessels.(62) 
Evaluation of these differences is key to developing physiologically healthy blood 
vessels for effective treatment.  
1.7 Preview of the Thesis 
 
 An in-depth review of the role that the extracellular matrix plays in the 
angiogenic process is given in Chapter 2. The development of the matrix is a 
complex interplay with the sprouting of new blood vessels during angiogenesis. If 
the matrix is incomplete or lacking one or more key components, the resulting 
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blood vessel sprouts may also lack stabilization cues and not function properly. 
Chapter 3 presents the in vitro assay design and development process, and the 
completion of the first specific aim. Following is Chapter 4, where the fully 
developed assay is used to address the second experimental aim that compares 
in vitro functional permeability differences for networks of capillary blood vessels 
formed in the presence of different stromal cell types. In vitro mechanistic cues 
and phenotypic differences in capillary growth with varying stromal cell types are 
also explored here. Chapter 5 brings the experimental plan full circle to an in vivo 
setting. Ultimate differences in functionality across the different treatment groups 
are compared, and stromal cell differentiation is investigated. Finally, the key 
findings and results are summarized in Chapter 6, and the ultimate translational 
applications of this work for the field of therapeutic angiogenesis are discussed.  
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CHAPTER 2 
An In-Depth Review of the Role of the Extracellular Matrix in 
Angiogenesis 
 
2.1 Introduction 
 
 During angiogenesis, the ECM dynamically evolves, changing and 
adapting to cellular processes that are taking place within its structure.  As ECs 
differentiate into tubular structures containing lumens and associated pericytes, 
significant matrix remodeling occurs.  Proteinases carve out areas to allow for 
invasion of the nascent tubular structures into the surrounding stroma, creating 
new vasculature in response to hypoxia.  A new basement membrane is laid 
down, and supporting interstitial matrix is layered beneath the newly formed 
structures.  This chapter will discuss angiogenesis as it relates to the surrounding 
ECM, the various proteinases that are able to modulate key steps of this process, 
and finally, the link between ECM mechanical properties and cellular remodeling 
during angiogenesis.   
 Vasculogenesis and angiogenesis are two distinctly different processes by 
which blood vessels form (Figure 2.1).  In embryonic development, angioblastic 
cells assemble into a primary capillary plexus to create nascent vasculature de 
novo via vasculogenesis.  By contrast, angiogenesis refers to the formation of 
capillaries via branching from existing vasculature after initial embryonic 
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development.  This requires a complex series of events starting with basement 
membrane degradation of the existing vasculature, followed by endothelial cell 
activation, migration, and proliferation, organization into immature vessel sprouts 
with leading tip cells, maturation and vessel stabilization via mural cell 
association, and finally, basement membrane deposition and pruning of the new 
vessels in response to the physiologic demands of the tissue.[5]  Each step in 
this process requires interaction between cells and their surrounding ECM.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 A balance between pro- and anti-angiogenic proteins, known as the 
‘angiogenic switch’, is crucial to the control of angiogenesis, with soluble factors 
and insoluble factors regulating this switch.  When the scale is tipped in favor of 
Figure 2.1: Schematic depiction of the two different processes by which new blood vessels
form in the body. Vasculogenesis typically occurs in development, with angiogenesis occurring
throughout life.  This chapter focuses on how the ECM is remodeled during the latter process.
(Figure reproduced from [1] with permission from Elsevier.)  
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molecules that inhibit angiogenesis, the switch is ‘off’ until the levels of activating 
(pro-angiogenic) molecules are increased and able to overcome the inhibiting 
molecules.  In healthy adults, the switch is typically maintained in the ‘off’ 
position, unless a pathological state which requires the formation of new 
vasculature occurs, such as cancer, wound healing, or ischemic disease.  (In 
cancer, tumor growth beyond a threshold is achieved in part by recruiting host 
vasculature; however, because a detailed discussion of tumor angiogenesis is 
beyond the scope of this chapter, readers should instead refer to other reviews 
on the topic.[6])  Many signals can tip the switch in favor of angiogenesis, such 
as hypoxia, low environmental pH, mechanical stresses, tumor growth, or the 
presence of immune or inflammatory cells.  Soluble growth factors, such as 
vascular endothelial growth factor (VEGF), platelet-derived growth factor 
(PDGF), basic fibroblast growth factor (FGF), and hepatocyte growth factor 
(HGF), are potent pro-angiogenic factors.  Stabilizing immature vessels requires 
molecules such as angiopoietins-1 and -2, TGF-β, and sphyngosine-1 phosphate 
(S1-P), which are also considered pro-angiogenic.  On the other side of the 
balance, suppressive signals from angiogenesis inhibitors include α-interferon, 
platelet factor-4, and thrombospondin-1, as well as other cryptic protein 
fragments.[7, 8]  Matrix metalloproteinases (MMPs) and their endogenous 
inhibitors can also be considered in the context of the angiogenic switch, as they 
function as both pro- and anti-angiogenic molecules and are essential in each 
step of capillary formation and remodeling.[9] 
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2.2 Changes in the ECM Accompany Each Stage of Angiogenesis 
 
 During the initial stages of angiogenesis, contact between ECs and the 
ECM is a key controller of angiogenic signaling.  ECs must adhere to the ECM in 
order to properly migrate, a necessary requirement for initiating angiogenic 
sprouting.[10]  The ECM immobilizes angiogenic cytokines, and thus coordinates 
signals transduced to ECs via both growth factor receptors and integrin cell 
adhesion receptors.[10-12]  Integrins, in turn, can regulate EC proliferation, 
survival, and the formation of functional vessel lumens.[12-15]  If the ECs fail to 
adhere to the ECM, proliferation ceases and angiogenesis thus also stops.[11, 
16-19] 
 At the earliest stages of angiogenesis, the basement membrane, consisting 
primarily of laminin-1 and type IV collagen, gets degraded to expose the ECs to 
the surrounding interstitial matrix.[20]  In a quiescent state, the basement 
membrane helps insulate the ECs from this interstitial matrix and inhibits EC 
invasion and migration.[11]  Following its degradation, a gradient of ECM 
components and the cytokines attached to them provide a set of cues to direct 
EC motility.  In wound healing, for example, the interstitial matrix consists 
primarily of fibrin and type I collagen, and supports subsequent EC migration and 
sprouting.[21]  VEGF plays a particularly critical role at this stage, as it is known 
to induce α1β1 and α2β1 integrin expression, both of which bind type I collagen.  
Type I collagen also helps to transform the leading ECs into a tip cell 
phenotype.[22]  One mechanism known to disrupt angiogenesis for therapeutic 
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or alternative purposes is to disrupt the formation of the collagen triple helix via 
alteration of the prolines.  This results in a cessation of collagen recognition and 
binding by the ECs, effectively halting angiogenic invasion and tubule 
formation.[23] 
 Once a nascent tubule escapes the basement membrane and begins to 
invade the interstitial matrix, extension of the capillary sprout begins.  Type I 
collagen induces nascent cord formation and a migratory EC phenotype in part 
by suppressing cyclic AMP, which causes increased actin polymerization and 
stress fiber formation within the EC cytoskeleton.[11]  This enables the ECs to 
generate substantial contractile forces and apply tension to the matrix over 
relatively large distances, which in turn supports capillary cord formation along 
the matrix fibers.  Other cell types do not migrate and produce cords when 
implanted in fibrin or collagen gels in the same way.[24]   Disruption of vascular 
endothelial cadherin (VE-cadherin) intercellular junctions via signaling 
mechanisms induced by collagen I binding also help to induce initial sprouting of 
ECs from a base vessel.[20]  Disrupted of their quiescent cell-cell contacts, ECs 
begin to migrate and develop into nascent cords.[23, 25] 
 The next steps in the angiogenic process include the formation of hollow 
lumens, followed by maturation of the nascent vessels.  As previously mentioned, 
integrin-mediated interactions between ECs and collagen, fibrin, and fibronectin 
provide key instructive signals.[26-28]  α2β1 and α1β1 are known collagen 
receptors, while αVβ3 and α5β1 are known fibronectin receptors that also permit 
EC interactions with fibrin.  Lumen formation is dependent on the formation of 
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these integrin-dependent intracellular vacuoles that are initially formed by the 
process of pinocytosis, in which small vesicles form to create pockets within the 
cell.  These vacuoles fuse together by exocytosis between adjacent ECs and 
start to direct an apical-basal organization and polarization.[29, 30]  This 
polarization requires membrane type-MMP (MT-MMP) to interact with the ECM at 
the exterior of the newly formed lumens.  The roles of these MT-MMPs will be 
discussed in greater detail later in this chapter.   
 The final step in the angiogenic process, tube stabilization, coincides with the 
production of laminin to form a new basement membrane along the basal surface 
of the nascent tubules.  Integrins α6β1 and α3β1, which bind ECs to specific 
laminin isoforms, are known indicators of capillary maturation.[31, 32]  The 
expression of these integrins suppresses several signaling pathways, and 
triggers EC quiescence.[33, 34]  The laminin-rich basement membrane also 
provides an interface with which both ECs and stabilizing pericytes can 
interact.[11] 
2.3 Proteinases Involved in Angiogenesis 
 
 The ECM must be broken down and reformed for many processes 
throughout life, including embryonic development, various morphogenic 
processes, cellular reproduction, and tissue remodeling.  The matrix itself serves 
as a platform for cell growth and support, but is also capable of controlling 
cellular attachment, proliferation, migration, and differentiation of cells via cell-
ECM interactions.  Many cytokines and growth factors can also be sequestered 
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in the matrix and stored for later use. Several different types of angiogenic 
proteinases modulate the ECM in varying ways to influence angiogenesis.  Some 
proteases indirectly promote EC proliferation, while others degrade the ECM to 
allow for tunneling ECs to invade and form tubules.  Others control growth factor 
release from the matrix, altering cues that can direct or inhibit the angiogenic 
process.  A final group of proteinases also controls cell adhesion to the matrix, 
inducing polarity within the blood vessels.  These adhesions may direct cells to 
migrate, proliferate, or remain quiescent, based on the levels of varying integrins 
expressed, and the contents of the matrix to which they bind.  MMPs are the 
main degradative enzymes responsible for modulating the ECM in a tissue.  They 
are always contributing to the evolving matrix as it changes in different ways to 
support and encourage various cellular processes.  In addition to both 
membrane-bound and soluble MMPs, ADAMs are another important group of 
proteins that influence ECM remodeling.  A final grouping of players is the tissue 
inhibitors of metalloproteinases (TIMPs), which can control angiogenesis and 
subsequent matrix remodeling by maintaining vascular quiescence and halting 
angiogenic cues to maintain the angiogenic switch in the “off” position.  
A. Soluble Matrix Metalloproteinases 
 
 Secreted matrix metalloproteinases are a family of zinc-containing 
endopeptidases that are able to degrade various ECM components.  They are 
produced as pro-enzymes that are proteolytically processed to become activated.  
A sulfhydryl group in the pro-domain of all MMPs, known as a “cysteine switch,” 
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is able to work in sync with the zinc ion of the catalytic site to maintain cell 
quiescence.[35]  By disrupting this cysteine-zinc binding, the MMP takes the first 
step toward activation.[36]  
 In general, the naming scheme follows a simple numerical order, starting 
with the first to be discovered, MMP-1, which acts on collagens.  It was originally 
discovered when collagen gels were degraded by tadpole fin explants.  The rest 
of the MMPs are divided into subgroups based on domain structure and 
substrate specificities: matrilysins (MMP-7 and MMP-26), collagenases (MMP-1, 
MMP-8, MMP-13, and MMP-18), stromelysins (MMP-3, MMP-10, and MMP-11), 
gelatinases (MMP-2 and MMP-9), enamelysins (MMP-20) and epilysins (MMP-
28), and others that don’t fit into one of these subgroups (MMP-19, MMP-21, 
MMP-22, MMP-23, and MMP-27).[37-39]  MMPs can also be classified based on 
the basic domain groups that are included in their structures.  All MMPs have 
three common structural domains: the “pre” or signal sequence, the pro-peptide 
domain, and the catalytically active domain (Figure 2.2). MMPs-7 and -26 contain 
only these 3 domains, have a broad range of substrate specificity, and are able 
to degrade many ECM proteins.[40-42] Addition of a hemopexin domain 
connected to the core region via a proline-rich hinge region at the catalytic 
domain allows for enhanced substrate specificity over those containing only the 
three basic regions.  This hinge region is also responsible for binding the family 
of specific MMP inhibitors (TIMPs).  Some examples of hemopexin-domain 
containing MMPs are collagenases, which degrade the native helix of fibrillar 
collagens such as types I, II, and III, as well as stromelysin-1 and -2, enamelysin, 
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metalloelastase, and MMPs-19, -22, and -27, which again don’t fit into a specific 
structural class of MMPs.[37]  These stromelysins, with their hemopexin 
domains, still have a rather broad substrate specificity, degrading several groups 
of ECM proteins, including proteoglycans, fibronectin, and laminin.[36]  Another 
similar grouping is the gelatinases (MMPs-2 and -9) containing three head-to-tail 
cysteine-rich fibronectin type II-like repeats within the catalytic domain.[40, 43]  
These MMPs also degrade types IV, V, VII, and X native collagens, as well as 
denatured collagen (gelatin), fibronectin, and laminin.[43]  When the cysteine-rich 
repeats are instead furin-susceptible sites, stromelysin-3 and epilysin are 
classified as a grouping.  Finally, there are two outlying MMPs, MMP-21, which 
does not have a hinge region at all, and instead contains a vitronectin-like region 
within the propeptide region, and MMP-23, which also lacks the hemopexin 
Figure 2.2: Schematic representation of the structures of MMPs and ADAMs. Both protease families
contained conserved features, a “pre” or signal sequence, a propeptide domain (pro) (with either a
cysteine switch or a furin-susceptible site), and a catalytic, Zn-binding domain. Additional sequences
in some MMPs include a hinge region (H) and hemopexin domain, and other features not shown
here.  ADAMs contain a disintegrin domain, a cysteine-rich motif, an EGF repeat, a transmembrane
domain, and a cytoplasmic tail. 
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domain, containing a cysteine and proline-rich region followed by an 
immunoglobulin-imitating region.[44]   
Soluble MMPs can have both pro- and anti-angiogenic roles.  Their pro-
angiogenic capacity is perhaps more obvious, given their ability to degrade ECM 
components and jumpstart the path toward angiogenesis.  Many growth factors 
and cytokines are known to upregulate EC basement membrane degradation, as 
well as EC proliferation, migration, and differentiation into a pro-angiogenic 
phenotype.  Examples of these molecules are VEGF, bFGF, and several 
interleukins, which increase the amounts of inactive[45] and active[46] MMP-2 
and MMP-9.[47]  However, because certain ECM cleavage products have anti-
angiogenic properties, MMPs may also be considered anti-angiogenic as 
well.[48] 
 
A.1. Pro-Angiogenic Roles of Soluble MMPs 
 During basement membrane degradation, a subgroup of ECs, known as 
“tip cells”, initiate sprouting.  These cells possess high proteolytic activity, 
enabling them to successfully break down the matrix and tunnel through the 
interstitial ECM and hypoxic tissue.[49]  Upon signaling to initiate sprouting, the 
tip cells must first proteolyze the capillary basement membrane, which is 
primarily comprised of laminin, collagen IV, heparin-sulfate proteoglycans, and 
entactin.[50]  Multiple MMPs can degrade these ECM components: MMP-2, 
MMP-3, MMP-7, MMP-9, MMP-10, MMP-12, and MT1-MMP.[37]  As mentioned 
previously, two important growth factors in the initiation of the angiogenic 
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cascade, VEGF and bFGF, produce vesicles containing pro-MMP-2 and pro-
MMP-9, as well as MT1-MMP.  Upregulation of these MMPs is thus associated 
with increased basement membrane invasion abilities of ECs.[51]    
 After the basement membrane has been broken down, ECs induce MMP 
expression from interstitial cells by secreting extracellular matrix 
metalloproteinase inducer (EMMPRIN).[52]  The majority of MMP production may 
be from these surrounding interstitial and inflammatory cells present in the 
matrix, rather than the ECs forming the actual new capillary sprouts.  Interstitial 
flow from the vasculature to the lymphatics, which is enhanced following 
degradation of the basement membrane barrier, combined with this increased 
MMP production, creates chemotactic gradients that further encourage EC 
invasion into the ECM.  This is perhaps achieved by the interaction of various 
ECM breakdown products with the surface of the ECs.[53]  Despite significant 
differences in pathologic and physiologic microenvironments, only small changes 
in soluble MMP expression are observed.[54]  For example, switching from a 
physiologic ECM containing mostly collagen I to a provisional ECM comprised of 
fibrin, fibronectin, and vitronectin typically found during wound healing or 
prolonged ischemic diseases, results in only slight modulation of the MMP 
expression profile.[55]  
 Recent work suggests that there may be no single proteolytic mechanism 
utilized by ECs to degrade the ECM.  Instead several MMPs are likely used in 
complement, and the specific combination and ratio of MMPs expressed and 
utilized depends on the identity of the matrix as well as the identity of stromal cell 
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types that interact with the ECs.  For example, when adipose-derived stem cells 
or fibroblasts were included as interstitial cells to induce capillary sprouting in a 
fibrin matrix, the plasminogen activator-plasmin axis was the preferred proteolytic 
mechanism utilized for capillary invasion into the matrix and tubule lengthening, 
while MMPs appeared to play a distinct role regulating capillary diameter and 
stabilization only.  In contrast, when mesenchymal stem cells from bone marrow 
were used in place of the adipose-derived cells, MT-MMPs were the sole 
proteases for ECM invasion and sprouting.[56]  
 Further work illustrating knockdown of either of the gelatinases, MMP-2 
and MMP-9, suggests that these two proteinases may work in concert to remodel 
the ECM during angiogenic processes.  When one of the two is targeted for gene 
knockdown, sprouting is still able to occur. MMP-9 is unable to degrade type I 
collagen alone, so thus it does not serve to encourage tunneling and sprouting of 
ECs during angiogenesis via matrix proteolysis directly.  Instead, its pro-
angiogenic capacity may lie in its ability to release bound VEGF (secreted by 
stromal cells) from the matrix to induce sprouting.  It is also capable of activating 
TGF-β, resulting in promotion of tissue remodeling.[57, 58]  During in vivo wound 
healing and hind limb ischemia studies, the peak activity levels of these MMPs 
coincide with granulation tissue formation, fibroblast migration into the tissue, and 
vascularization of the wound.[59, 60]  Several research groups have now 
fabricated synthetic hydrogels with linkages sensitive to MMP-2 and MMP-9 so 
that cellular invasion can occur in much the same way as in hydrogels of natural 
composition (e.g., collagen or fibrin).  In vitro studies using RGD-functionalized 
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versions of these MMP-sensitive gels have demonstrated EC adhesion and 
capillary sprouting by mimicking key elements found in natural matrix 
proteins.[61, 62]  Furthermore, tethering growth factors such as VEGF to the 
matrix via proteolytically sensitive linkages recapitulates the growth factor 
sequestration capacity of physiologic ECMs.[63]    
   
A.2. Anti-Angiogenic Roles of Soluble MMPs 
 As mentioned previously, MMPs can be considered to be both pro- and 
anti-angiogenic.  MMP expression and activity can impede blood vessel 
formation via one of two possible mechanisms.  First, overactive MMPs can 
compromise ECM stability, which may result in vascular regression.  Second, 
MMP activity can generate matrix fragments with anti-angiogenic capabilities.   
 With respect to the first possibility, the process of angiogenesis typically 
culminates with vascular pruning.  During this process, vessels that have not 
been stabilized regress as some of the interstitial collagen is broken down.  
Specifically, plasmin-mediated activation of MMPs-1, -10, and -13 has been 
shown to induce vascular regression as each of these MMPs (although 
predominantly MMP-1) can digest interstitial collagens.[64] This subset of MMPs, 
in conjunction with MMPs-2, -9, and MT1-MMP, may act together to digest 
multiple different ECM components based on these enzymes’ specificities for 
different substrates.[64, 65]  The first subset breaks down native type I collagen, 
while the gelatinases more efficiently degrade denatured collagens.  A direct 
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correlation between the levels of active MMPs in maturing capillary beds and the 
levels of vascular regression has been reported.[66, 67]   
 With respect to the second possibility, the proteolytic degradation products 
of MMPs are anti-angiogenic.  Proteolytic degradation of collagen IV, one of the 
primary components of basement membrane, generates anti-angiogenic 
fragments that include arrestin, canstatin, tumstatin, and metastatin.[38]  MMP-9 
predominantly produces free tumstatin, as well as smaller amounts of arresten 
and canstatin.  Other MMPs, including MMP-2, -3, and -13, are also able to 
liberate tumstatin, although not as efficiently as MMP-9.[68]  Tumstatin targets 
the αVβ3 integrin, which is not expressed at measurable levels in physiologic 
angiogenesis, but is seen at much higher levels in tumor angiogenesis.  Studies 
have explored the possibility of using tumstatin to reduce pathologic 
angiogenesis.[68]  Arrestin, another collagen IV breakdown fragment, binds the 
α1β1 integrin receptor for collagen I, and inhibits EC proliferation, as well as 
migration and further tube formation in vitro.  Similarly, collagen XVIII is a 
component of the interstitial matrix beneath the basement membrane of the 
vasculature.  Collagen XVIII breakdown products are endostatin and neostatins, 
which are small, varying molecular weight molecules that are the further 
breakdown products of endostatin.  MMPs-3, -7, -9, and -13, as well as MT1-
MMP, act on collagen XVIII to produce these fragments.  Endostatin affects 
VEGF signaling, EC proliferation and migration as well, in part by acting on the 
α5β1 integrin.[69-72]  Another unique function of endostatin is its ability to inhibit 
MT1-MMP and MMP-2 activities.[73]  
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B. Membrane-Type Matrix Metalloproteinases (MT-MMPs) 
 
 The membrane-type MMPs (MT-MMPs) represent another grouping of 
MMPs, so named because they are bound to the cell’s plasma membrane via 
either a C-terminal transmembrane domain or a glycophosphatidyl inositol (GPI) 
anchor.[43, 74]  Both classifications include a “pre” region, a propeptide region 
with a furin-susceptible site, a catalytic domain, a hinge region, and a hemopexin 
domain.  After furin activation intracellularly, the proteinase gets processed and 
sent to the cell membrane, where the catalytic, hinge, and hemopexin domains 
lie extracellularly.  These external regions are held at the cell surface by a 
transmembrane region attached to a short amino acid tail residing in the cell 
cytoplasm, or a GPI domain that is fixed in the cell membrane.  These MT-MMPs 
provide spatial control of matrix breakdown directly at the cell membrane 
surface.[37]  MT-MMPs degrade gelatin, fibronectin, and aggrecan, as well as 
several other ECM substrates.[41, 42]  
 Once nascent capillaries have formed, a basement membrane, a hallmark 
of a more mature vessel network, is deposited. Pericytes play a key role in this 
process.  These cells are recruited from the host stroma in part via the secretion 
of PDGF-β by ECs.  PDGF receptor-β signaling then initiates a cascade of 
events that control pericyte-EC binding, migration to the site, and proliferation.  
Interestingly, all of these processes are in some manner controlled by MT1-
MMP.[75-77]  Co-cultures of ECs and stromal cells of various origins in 3-D gels 
yield stable, pericyte-invested networks of capillaries characterized by the 
presence of basement membrane subjacent to the ECs along with the 
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periendothelial location of the stromal cells (Figure 2.3).[2] In the absence of 
stromal cells, ECs express MT1-MMP, with very little basement membrane 
production, even at later time points.  If stromal cells are included with ECs in 
culture, MT1-MMP expression is undetectable in the capillary stalks.  The ECs in 
the stalk instead produce basement membrane proteins, and the expression of 
MT1-MMP is restricted to the tip cells. Similar expression profiles have also been 
see in vivo.[49]  
 Further examination of the newly deposited basement membrane 
production yields some other interesting observations.  The EC TIE-2 receptor is 
preferentially expressed in the stalk portion of a maturing capillary sprout, but are 
notably absent in the tip ECs.  This expression is thought to be controlled by the 
pericytes, which produce  Ang-1 to signal to the ECs via the TIE-2 receptor.[49, 
78]  This Ang-1/TIE-2 interaction is one mechanism by which pericytes and 
SMCs can regulate MMP activity of ECs.  An alternative, and much more direct, 
means to achieve this control is via TIMP-1 secretion.  TIMP-1 inhibits soluble 
Figure 2.3: Three-dimensional co-cultures of ECs and stromal cells generate stable, pericyte-invested
capillary networks in vitro.  In these experiments, bone marrow-derived mesenchymal stem cells (MSCs)
MSCs were distributed throughout a fibrin-based 3-D ECM in the presence of microcarrier beads coated with
ECs. (A.) After 7 days, cultures were fixed and IF stained at day 7 for F-actin (green) and collagen IV (red) to
visualize basement membrane deposition (white arrows). Scale=50 μm. (B.) MSCs expressing GFP were
interspersed with mCherry-transduced ECs.  Physical association of the ECs and MSCs were observed
(white arrows). Scale=25 μm. (C) Cultures containing mCherry-transduced ECs and MSCs were fixed and IF
stained for pericyte markers α-SMA (aqua) and NG2 (white). DAPI-stained nuclei are visible in the blue
channel. Scale=50 μm. (Figure reproduced from [2] with permission from Elsevier.) 
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MMPs, but also appears to stabilize vessels by inducing basement membrane 
protein production.[79]  Other TIMPs also work in conjunction with both cell types 
to inhibit angiogenic sprouting and stabilize nascent vessels.  TIMP-3 is secreted 
by perivascular cells, and is then presented to the ECs via heparin sulfate 
proteoglycans in the basement membrane, which suppress MT1-MMP activity 
and encourage sprouting of the ECs.(Figure 2.4)[3, 80]  Furthermore, all EC 
interactions with associating pericytes via Ang-1 or PDGF serve to inactivate and  
inhibit MT1-MMP after the basement membrane has been reproduced and to 
ensure vascular quiescence. 
  
Figure 2.4: Schematic diagram illustrating the contribution of TIMP-2 and -3 to pericyte-induced
vascular tube stabilization, as proposed in [3]. TIMP-2 is derived from ECs, whereas TIMP-3 is
produced by pericytes. Together, they contribute to vascular stabilization by inhibiting a variety of
MMPs, ADAMs, and VEGFR-2. The initiation of tube stabilization requires the blockade of both
EC tube formation and EC tube regression, which further leads to the cessation of EC activation
and the development of EC quiescence. Pericytes are required for ECs to assemble basement
membrane matrices, which may locally capture and present TIMP-3 to ECs through heparin
sulfate proteoglycans. (Figure reproduced from [3] with permission from The Rockefeller
University Press.) 
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  C. A Disintegrin and Metalloproteinase (ADAM) 
 
 ADAMs are a family of secreted and transmembrane proteins that control 
cell adhesion, as well as proteolytic processing of the ectodomains of cell surface 
receptors and signaling molecules.[81]  Like previously described MMPs, ADAMs 
have both pre- and propeptide domains, with the pro- domain acting as an 
intramolecular chaperone that controls protein folding[82] and enzyme latency via 
a cysteine-switch mechanism.[83, 84]  At this point, the structures differ, with 
ADAMs having a disintegrin-like domain with a loop that is able to interact with 
neighboring cell integrins.[85]  Following this region, a cysteine-rich domain, then 
an EGF-like domain, followed by a membrane-spanning region and a 
cytoplasmic tail.  The cytoplasmic domain is able to interact with proteins of 
intracellular signaling importance, as well as to control trafficking of proteins 
(Figure 2.2).  ADAMs are named such due to their original structural homology to 
the small proteins of hemorrhagic snake venoms that were able to bind platelet 
integrin α2bβ3a to block platelet aggregation.[86] 
 Because ADAMs are an active family of metalloproteinases, they are able 
to cleave ECM proteins and cause degradation of the bulk ECM in a locale.  One 
example of this is ADAM-9, which is able to cleave laminin and promote 
invasion.[87]  Several studies have shown a connection between ADAM-10 and 
cleavage of adhesion molecules such as VE-cadherin, where the ADAM is able 
to disassemble the junctional contacts that control permeability and assist with 
encouragement of EC migration and tubule sprouting.[11, 88]  Other ADAMs that 
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are known to control ECM degradation and release activators of ECs to a 
migratory phenotype that will start the angiogenic cascade, are ADAMS-15 and   
-17.[11]  ADAMs are also able to induce shedding of adhesion molecules such as 
PECAM-1, or their activity may mobilize growth factors, chemokines, or other 
soluble factors that can influence angiogenic processes.[89]  
D. Inhibitors of Matrix Metalloproteinases 
 
 Tissue inhibitors of metalloproteinases (TIMPs) are the main enodogenous 
inhibitors of MMPs.  There are four mammalian TIMPs that have been identified 
and characterized within the literature.  They are all known to regulate MMP 
activity during periods of tissue remodeling, with molecular weights between 20 
and 29 kDa.[90]  All TIMPs inhibit MMP substrates in a 1:1 stoichiometric 
ratio,[91] with each TIMP binding the active site cleft in the catalytic domain of an 
MMP, in the same manner as an ECM substrate would bind the MMP.[44]  Each 
TIMP has disulfide bonds of a three loop N-terminal domain, which is where 
interaction with the catalytic domains of MMPs occurs, and a complementary 
three loop C-subdomain.[92]   
 All TIMPs are secreted proteins, but TIMPs-2, -3, and -4 can all be found 
near the surface of a cell, in association with different MMPs.[93]  All four TIMPs 
are known to inhibit active forms of all MMPs; however, their inhibition abilities 
vary widely.  The main exception to this rule is that TIMP-1 is a poor inhibitor of 
MMP-19, MT1-MMP, and MT3-MMP.[94]  TIMP-3 easily inhibits many of the 
ADAMs.[95]  Examples of preferential binding are the ability of TIMP-1 to 
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preferentially bind with pro-MMP-9, and TIMP-2 preferentially binding with pro-
MMP-2 to inhibit conversion to active forms of these MMPs.[96, 97]  
 TIMP-2 has a special functional role in controlling the activation of pro-MMP-
2, with MT1-MMP also acting as a modulator.  This activation step takes place on 
the cell surface, thus the need for inclusion of MT1-MMP for activation.[98]  
According to Strongin et al., the increased activation of MMP-2 in the presence of 
TIMP-2 is the result of the N-terminal inhibitory domain of TIMP-2 binding to the 
active site of MT1-MMP, and the C-terminal domain of TIMP-2 interacting with 
the C-terminal hemopexin domain of pro-MMP-2.[99]  An additional unique 
feature of TIMP-2 is its ability to suppress angiogenesis by reducing EC 
proliferation cues from bFGF via its C-terminal region. [100] 
 TIMP-3, as briefly mentioned earlier, can inhibit both MMPs and the ADAM 
family of proteinases.[44]  TIMP-3 is also known to block VEGF to VEGFR-2 
binding, which further contributes to the anti-angiogenic capabilities of TIMP-
3.[101]  A third unique property of TIMP-3 is its restricted diffusion caused by its 
tight binding to heparin sulfate proteoglycans in the surrounding ECM.  Because 
it does not readily diffuse, it is thought that TIMP-3 instead functions to regulate 
angiogenesis after the angiogenic switch has been flipped into an “on” position.  
As MMP degradation of the ECM liberates the matrix-bound TIMP-3, it can then 
inhibit any subsequent MMP activation at the cell-ECM level.[102]  Normally, 
TIMP-3 functions to form complexes via its C-domain with MMPs-2 and -9, thus 
effectively slowing pro-angiogenic signaling. [92]   
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 TIMP-4 is found mainly in the human heart, with low levels of the inhibitor 
found in the kidney, colon, placenta, and testes.[103]  Levels are dysregulated in 
various cardiovascular diseases.  This TIMP functions mainly to reduce EC 
motility, as well as proliferation, and induce apoptosis as well.  In in vivo models, 
addition of TIMP-2 results in suppression of angiogenesis, while addition of 
TIMP-4 is not able to have this same effect.[104]  TIMP-4 deficient mice instead 
showed reduced cardiac function with aging, due to increased apoptosis of 
cells.[105]  
 An additional inhibitor of MMPs, while not in the TIMP family, is the GPI-
anchored glycoprotein, reversion-inducing cysteine-rich protein with kazal motifs 
(RECK).  It is known to inhibit the release of pro-MMP-9 from the EC surface.  It 
also effectively inhibits MT1-MMP, which will result in inhibition of MMP-2, as 
previously discussed.[106, 107]  In RECK knockout mice, blood vessels cannot 
reach a mature stage, and mice die in utero.  Overexpression of RECK in tumor 
 
Figure 2.5: A simplified schematic of the current concepts depicting the roles and regulation of MMPs as 
they pertain to matrix remodeling.  Figure reproduced from [4] with permission from The American 
Physiological Society.) 
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models results in a reduction of new blood vessel sprouting to sufficiently nourish 
the tumor.[90]  An additional proteinase inhibitor, α2-macroglobulin, is the primary 
MMP inhibitor found in blood plasma.[108]  Finally, thrombospondin-1, a known 
inhibitor of angiogenesis, is also known to inhibit pro-MMP-2 and pro-MMP-9 
from becoming activated.  Thrombospondin-2 is also known to complex with 
MMP-2 to increase clearance via receptor-mediated endocytosis.[108] 
 A schematic summarizing many of the effects of soluble and membrane-
bound MMPs, as well as the TIMPs, is shown in Figure 2.5.  
2.4 Effects of Stromal Cells on the ECM 
A. Stromal Cells Influence ECM Synthesis and Degradation 
 
 It has been widely established in the literature that the presence of 
pericytes covering EC tubules results in stabilization of the vessels, a decrease in 
vascular pruning, and decreased permeability of the nascent vessels.[109]  
Pericytes are a source of angiopoietin-1, which acts on EC TIE-2 to stabilize 
these heterogeneous cell-cell junctions.[110]  Recent findings have shown that 
EC-pericyte interactions occur after ECs carve out “vascular guidance tunnels” 
within the ECM, which provide physical space for the EC-pericyte interactions to 
take place.  Stratman et al. showed that the pericytes are recruited to the 
ablumenal surface and are able to move along the EC tubules through these pre-
formed spaces to regulate tubule maturation and vascular basement membrane 
assembly.[111, 112]  Basement membrane is deposited between ECs and 
pericytes within these tunnel voids.  Further work by this group showed that 
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PDGF-BB and HB-EGF are necessary for pericytes to accumulate within these 
tunnels and along EC tubules, and also for proper basement membrane 
deposition.  Without these growth factors directing the behavior of the pericyte-
EC interactions, their data suggest that no basement membrane will be laid 
down.[113]  This growth factor-pericyte interplay is known to be regulated by 
MT1-MMP. Active MT1-MMP directly controls the binding to PDGF receptor-B of 
pericytes after PDGF- β secretion by ECs.  This cascade of events then controls 
pericyte migration to sites of need along the vasculature, as well as proliferation 
to induce greater vasculature stabilization and angiogenic quiescence.[75, 77]  
VEGF, an important initial cue for increased vessel permeability followed by 
basement membrane degradation and EC sprouting, also affects pericyte 
coverage.  Treatment with VEGF antagonists results in increased pericyte 
coverage and improved microcirculatory function with lower permeability.[114, 
115] 
 The TIE-2 receptor of ECs on the stalks of sprouting capillaries is a 
signaling receptor that results in collagen IV expression throughout the stalk but 
not in the tip cells of capillary sprouts.  It is thought to be regulated by Ang-1 in 
the presence of vascular smooth muscle cells (vSMCs).[49]  When vSMCs are 
absent, the distinction between stalk and tip cells is eliminated, and MT1-MMP is 
expressed throughout the structure.[49]  Pericytes in co-cultures with ECs also 
express TIMP-1, which inhibits the activity of soluble MMPs and promotes 
basement membrane deposition by ECs.[79]  
43 
 As mentioned earlier, pericyte contact with EC tubules reportedly plays a 
role in basement membrane deposition.  Basement membrane proteins such as 
laminins and collagen IV are produced with the assistance of pericytes.  In 
quiescent vessels, these basement membrane proteins inhibit tube 
morphogenesis by blocking access to the interstitial collagens that encourage EC 
migration and invasion.  When pericytes are not present to encourage laminin 
deposition, ECs remain migratory, and vessel stabilization does not occur.  
Further work has also shown that EC-pericyte interactions induce production of 
fibronectin, nidogen-1, nidogen-2, and perlecan, as well as the laminins and 
collagen IV on the ablumenal surfaces of nascent EC tubules, all of which are 
constituents of basement membrane.[111]  Additional work in this area showed 
that ECs produced the elevated levels of fibronectin found during these EC-
pericyte interactions, while nidogen-1 was produced by the pericytes.  These two 
proteins are both known to be binding molecules for the basement membrane 
specifically.[11, 116]  Furthermore, fibronectin binds collagen IV and perlecan, 
and nidogen-1 binds collagen IV and laminin.  Thus, fibronectin and nidogen-1 
appear to be essential for assembly of the full basement membrane.[116]  
Collagen IV is mainly responsible for basement membrane structural support, 
and binds predominantly fibronectin and nidogen-1, and self-assembly of 
fibronectin that is induced by pericytes has a direct effect on collagen IV 
assembly as well.[111] 
 Most mature capillary networks within the body have approximately 20-
25% of their area covered by pericytes.[117]  Despite the fact that pericytes 
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cover only about one fourth of the total EC tubule area, they appear to control 
basement membrane production and maintenance along the full length of each 
tubule (see Figure 4).  This may be due to their ability to move along the tube 
surface.[117]   Collectively, these results suggest that heterotypic cell-cell 
contacts between ECs and pericytes, along with the constant pericyte motility 
along nascent tubules, are required events for basement membrane deposition 
and ultimate vessel stabilization.    
 While conventional wisdom suggests that stromal cells that differentiate 
into pericytes promote vessel stabilization, basement membrane production, and 
maturation of the interstitial ECM, there are several cases where stromal cells 
influence ECM protein degradation and subsequent remodeling. The recruitment 
of mural cells to the stalks of nascent EC tubules anatomically distinguishes tip 
cells from stalk cells, and leads to the further production of MMPs by the tip cells 
to facilitate their ability to break down and invade the matrix ahead of them.  In 
aging adults, pericyte coverage can decrease, causing ultimate ECM breakdown 
and angiogenic activity increases.[118]  Similar activities take place in various 
ischemic diseases and pathologies such as diabetes.   
B. Pericytes Modulate Integrin-Mediated EC-to-ECM Attachment 
 
 Integrins mediate EC attachment to the ECM, and cross-talk with several 
growth factor receptors, and thus are of critical importance in the process of 
angiogenesis.  ECs express a wide range of integrins depending on the location 
and state of activation of the cells.  The repertoire of integrins expressed by 
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quiescent ECs enables adhesion to components of an intact basement 
membrane.  On the other hand, angiogenic ECs upregulate the expression of a 
small subset of integrins, most notably the αvβ3 heterodimer, which has been 
reported to be required for angiogenesis.[119]  It has been proposed that this 
integrin is upregulated in angiogenic ECs to permit binding to a wide range of 
provisional matrix components, including fibrinogen, vitronectin, von Willebrand 
factor, and fibronectin. Consistent with a requirement for this integrin in 
angiogenesis, a landmark study showed that αvβ3 integrin antagonists promote 
tumor regression by inducing apoptosis of angiogenic blood vessels.[120]  There 
is some evidence that integrin α5β1 expression is also upregulated at the initiation 
of angiogenesis, perhaps because it allows the newly migrating ECs that are 
sprouting from a pre-existing vessel to bind the aforementioned components of 
the provisional matrix.[121, 122]  A complete discussion of integrins and their 
roles in both normal and pathologic angiogenesis is beyond the scope of this 
chapter.  (For an excellent review, the reader is referred to a paper by Stupack 
and Cheresh.[123])   
 However, two facts regarding integrin expression are particularly relevant 
in the context of this chapter on ECM remodeling.  The first is that the integrin 
expression profiles of ECs undergoing angiogenesis are different than those of 
quiescent ECs, as noted in the preceding paragraph.  This is due to the fact that 
angiogenic ECs are exposed to an interstitial matrix whose composition is 
significantly different than a basement membrane, as well.  The second is that 
pericytes appear to also be involved in the regulation of EC integrin expression 
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patterns.  ECs that are in contact with pericytes express α5β1 to attach to the 
basement membrane.  When pericytes are not present, expression of this 
integrin is down-regulated, and the nascent vessels remain in an unstable 
immature state (perhaps more appropriately called an angiogenic state versus a 
quiescent state).  Other integrin subunits with high affinities for basement 
membrane components (i.e. nidogens, laminins, and collagen IV), including the 
α3, α6, and α1 subunits, are also not expressed by the ECs in appreciable 
amounts when pericytes are absent.  In contrast, α2 integrin, which recognizes 
collagen I (a component of the interstitial ECM, but not the basement 
membrane), is expressed at high levels in ECs cultured alone in 3-D collagen 
matrices, but is down-regulated in EC-pericyte co-cultures after pericytes have 
been recruited to initiate vessel maturation.[111]  This study by Stratman et al. 
also showed that a strong induction of α3, α5, and α6 integrin mRNAs in ECs, 
combined with a dramatic increase in pericyte α1, α3, and α6 integrin mRNAs only 
when ECs and pericytes were cultured together and coincident with the 
deposition of basement membrane matrices.[111]  Thus, there appears to be a 
complex and dynamic crosstalk between the ECs and pericytes that governs the 
integrin expression profiles of both cell types.  These dynamic changes in integrin 
expression profiles permit EC adhesion to the interstitial matrix during the initial 
sprouting phases of angiogenesis, followed by the subsequent adhesion of both 
cell types to the EC-deposited basement membrane as the capillaries stabilize 
and mature.    
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2.5 Linking ECM Mechanical Properties and Remodeling 
 
 The ECM’s ability to regulate angiogenesis is complex and multivariate.  
Not only does it impact capillary morphogenesis via biochemical regulatory 
mechanisms, including through growth factor sequestration, integrin-mediated 
adhesion, and protease susceptibility, it also acts as an instructive structural 
framework to support sprouting and nascent capillary functionality. An additional 
feature of the ECM that has been proposed as a regulator of angiogenesis is its 
mechanical resistance to cell-generated tractional forces.[124] Evidence from 
several studies corroborates the idea that mechanical cues directly impact 
tubulogenesis.[125-132]  Vailhe et al. demonstrated that human umbilical vein 
ECs seeded on top of 2-D fibrin gels varying in concentration from 0.5 to 8 mg/ml 
only formed capillary-like structures on the softest of the gels.  The authors 
concluded that the ECs do not form capillary-like structures on the more rigid 
gels because the cells are unable to generate the necessary contractile forces to 
remodel the more rigid substrate.[127]  Another study conducted by Deroanne et 
al. showed that ECs seeded on collagen-functionalized polyacrylamide gels of 
different stiffness change morphologies from a monolayer to a tube-like 
phenotype as substrate rigidity decreases.[125]  In 3-D culture, Urech, et al. 
investigated angiogenic process extension in 3-D fibrin gels and manipulated 
their mechanical properties by adding exogenous factor XIII to form additional 
cross-links.[129]  Sieminski, et al. also studied the 3-D formation of capillary-like 
structures by two different types of ECs in freely-floating vs. mechanically-
constrained (attached) collagen gels, and concluded that changing the collagen 
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concentration modulates the formation of these structures by regulating the 
amount of traction force exerted by the cells.[126] Further evidence links EC-
generated traction forces with branching [130], the formation of capillary-like 
structures  [125, 126, 133], and the transcriptional control of soluble pro-
angiogenic molecules.[131]  A more detailed discussion of the role of ECM 
mechanics and EC-generated tractional forces is found elsewhere.   
 In the scope of this chapter, it is important to recognize that the 
mechanical properties of the ECM are highly dynamic due to active remodeling 
induced both by the ECs and stromal cells.  A study by Lee, et al. used second 
harmonic generation and two-photon excited fluorescence to show that ECs 
induce quantifiable alterations in local collagen matrix density via a process that 
involves cell-generated forces.[134] Another study by Krishnan, et al. tracked 
changes to the ECM during the process of angiogenesis using a 3-D culture 
model.[135]  The authors reported an overall softening of the ECM as MMP 
activity increased during the initial sprouting phase, and then a slow stiffening as 
the MMP activity held steady and sprouts increased in length during 
tubulogenesis.  Other studies have suggested that matrix stiffness may also 
indirectly modulate MMP activity in ECs [136-138]; however, the underlying 
mechanisms linking ECM mechanical properties and protease expression and/or 
activity remain to be elucidated.  
 In addition to EC-generated forces regulating angiogenesis, a recent study 
by Kilarski, et al. reported that external forces generated by myofibroblasts 
pulling on the ECM during wound contraction mediated the formation of vascular 
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loops by pulling on preexisting vascular beds.[139] This process, known as 
intussusceptive microvascular growth [140], demonstrates that stromal cells 
influence the process of angiogenesis in multiple ways.  Not only do they secrete 
pro- and anti-angiogenic soluble factors, some of which influence the expression 
and activity of certain MMPs, and act as pericytes to stabilize the nascent 
vasculature, they also generate local forces that dynamically remodel the ECM 
and preexisting tissue structures.  Understanding the complex interplay between 
ECs, stromal cells, and the ECM remains an ongoing challenge for the field.    
2.6 Conclusions 
 
 The ECM continuously remodels in response to multiple instructive cues 
during the complex process of capillary morphogenesis.  From early 
development of the capillary plexus in vasculogenesis, to the angiogenic 
sprouting of new vasculature in ischemic tissue in adults, many different 
proteinases work in concert with ECs and stromal cells to drive matrix 
breakdown, capillary sprouting, and subsequent maturation.  Various soluble 
MMPs, membrane-bound MMPs, ADAMs, and inhibitors of each of these active 
players, play important roles to maintain the balance between pro- and anti-
angiogenic cues in quiescent vessels, and to tip the scales to induce capillary 
morphogenesis and blood vessel development when needed.  An increasing 
body of literature strongly suggests that pericytes are not only essential in 
promoting the stabilization and long-term functionality of capillary networks, but 
they can also exert their influence on vessel formation in a multitude of ways.  As 
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discussed here, pericytes also dynamically communicate with ECs to influence 
matrix proteolysis, synthesis, integrin expression profiles, and the mechanical 
properties of the interstitial matrix, all of which can influence angiogenesis. 
Further work is needed to dissect the exact roles of these various players on 
matrix remodeling and angiogenesis. 
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CHAPTER 3 
Design and Optimization of an in vitro Assay to Assess 
Permeability in a 3D Co-Culture of Engineered Capillaries 
3.1 Introduction 
 
The tissue engineering field has seen only limited success because of a 
lack of functional vasculature to supply nutrients and oxygen to full thickness 
tissues.(1-3) To address this challenge, we have developed methods to engineer 
stable capillary-like structures in vitro in 3D fibrin gels, and used this platform as 
a model system to better understand the design rules which govern the formation 
of functional vessel networks. By starting with endothelial cells and different 
types of stromal cells, we were able to produce a network of vessels that are 
stable in culture, with hollow lumens and network architectures.(4, 5) This model 
of capillary morphogenesis was then further expanded to explore the functionality 
of these tissue engineered vessels and ensure that they function as normal 
healthy vessels with controlled permeability. This was done by developing an in 
vitro assay of inverse permeability, where a tracer was added to a bulk gel, 
allowed to diffuse freely, and then the amounts of tracer, both inside and outside 
the capillary lumens, were quantified. 
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The premise behind this model is that immature capillaries with incomplete 
cell-cell junctions are unable to regulate permeability, thus allowing tracer to 
enter the capillary lumens.(6-10) If the capillaries present are mature, competent 
cell-cell junctions between endothelial cells, as well as the presence of stabilizing 
pericytes, will block tracer from entering the hollow lumens of the capillaries 
(Figure 3.1). 
The methodologies required to produce an in vitro assay are discussed in 
detail here. First, the three dimensional fibrin tissue assembly where capillaries 
were cultured will be discussed. The traditional assay includes a layer of stromal 
cells on the upper surface of the fibrin constructs to provide cues for sprouting 
and capillary maturation.(11) For most of the following experiments, the assay 
has been altered slightly to include the stromal cells distributed throughout the 
Immature Early Sprout Mature Stabilized Capillary 
Figure 3.1. Model of inverse permeability used to determine capillary functionality kinetics in a 3D 
culture. Texas Red-conjugated dextran (70 kDa) is added to the bulk gel for 30 minutes and allowed to 
freely diffuse. Early capillary sprouts, which lack mature cell-cell junctions between the endothelial 
cells that form the tubules, will easily allow the tracer to be transported from the tissue space into the 
interior of the capillary. By contrast, mature capillaries that are stabilized by pericytes and possess 
more mature cell-cell junctions are capable of excluding the tracer from the lumen. 
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fibrin matrix. This potentially allows the stromal cells to adopt a pericyte-like 
phenotype and provide stabilization cues via direct contact with the capillary 
sprouts.  
Next, the steps to achieve successful imaging are discussed, altered, and 
optimized. The biggest challenge in developing an inverse assay to assess 
permeability in these 3D cultures was the addition of fluorescent tracer to the 
bulk gel. The addition of such a large volume of fluorescent material produced 
high levels of background and caused difficulties in optical imaging techniques. 
These hurdles were overcome by altering steps in the process, such as staining 
methods, quantification, and gel construction specifications.  
VE-cadherin junctional staining was used as a tool for imaging capillary 
cell-cell junctions between endothelial cells.  As an alternative, hCD31 staining of 
the endothelial cells was used to define the borders of the capillaries for the 
permeability assays.  Methods to quantify permeability are briefly discussed. 
Finally, optimization of the imaging methods for quantification was examined. 
The gel specifications were altered in order to eliminate excessive background 
signal during imaging.  All of these design features and optimizations required to 
achieve successful model function are discussed in the context of this chapter.   
3.2 Methods 
Cell Culture 
Human umbilical vein endothelial cells (HUVECs) were grown in fully 
supplemented Endothelial Growth Medium (EGM-2, Lonza, Walkersville, MD). 
Normal human lung fibroblasts (NHLFs, Lonza) were cultured in Media 199 
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(Invitrogen, Carlsbad, CA) supplemented with 10% FBS, 1% 
penicillin/streptomycin (Mediatech, Manassas, VA), and 0.5% gentamicin 
(Invitrogen) at 37°C and 5% CO2. NHLFs were used prior to passage ten. ECs 
were used at passage three. Cells were cultured in monolayers until reaching 
80% confluency and serially passaged using 0.05% trypsin-EDTA treatment.  
 
3D Bead Assay & Fibrin Tissue Assembly 
Endothelial cells coated onto microcarrier beads were embedded within a 
3D fibrin matrix, in which stromal cells were also distributed, to form stable 
capillary structures. A schematic diagram of the process can be found in Figure 
3.2. In more detail, four million HUVECs (p3) were harvested and coated on 
10,000 presterilized Cytodex (Sigma-Aldrich, St. Louis, MO) microcarrier beads 
(131 – 220 μm diameter) in 5 ml of EGM-2 in an inverted T-25 flask over a 4 hour 
incubation period with mild agitation every 30 minutes. After 4 hours, 5 ml of 
fresh EGM-2 were added and the total volume was transferred to a fresh T-25 
flask for incubation in standard cell culture position overnight. A 2.5 mg/ml bovine 
fibrinogen (Sigma-Aldrich) solution was made in serum-free EGM-2 and filtered 
through a 0.22 μm syringe filter. A 500 μl aliquot of the fibrinogen with 5% FBS 
was mixed with 50 pre-coated beads and polymerized by addition of 10 μl of 
thrombin (50 U/ml, Sigma- Aldrich) in a single well of a 24-well tissue culture 
plate. The mixture was incubated at 25°C for 5 minutes, and then at 100% 
humidity, 37°C and 5% CO2 for 25 minutes. In the standard assay configuration, 
25,000 NHLFs were plated on top of each gel after polymerization, and 1 ml of 
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fresh, fully supplemented EGM-2 was then added to the top of the gel. For some 
applications, stromal cells were distributed throughout the gel constructs rather 
than in a monolayer on top of the constructs. Media were changed every other 
day. 
 
Thin Gel Fabrication for Confocal Microscopy 
In order to produce gels that were thin enough for successful confocal 
imaging, the standard protocol was slightly modified. Beads were coated and 
fibrinogen solution was made in the standard manner outlined above. Either a 
125 or 150 μl aliquot of the fibrinogen with 5% FBS and 10,000 NHLFs were 
mixed with 25 pre-coated beads and polymerized by addition of 2.5 or 3 μl of 
thrombin (50 U/ml, Sigma Aldrich) in a single well of a #1 chambered 8-well 
coverglass. The mixture was incubated at 25°C for 5 minutes, and then at 100% 
humidity, 37°C and 5% CO2 for 25 minutes. 350 μl of fresh EGM-2 were then 
added to the top of the gel and medium was changed every day.  
.   
Dextran Tracer Selection & Addition to Fibrin Tissues 
 A 70 kDa dextran is above the known limit of freely permeable molecules 
that can diffuse from a capillary lumen to the external tissue under normal 
conditions.(10, 12) Dextran tagged with Texas Red was added to the bulk gel for 
30 minutes after media removal and allowed to freely diffuse. After 30 minutes, a 
series of three 10 minute washes with PBS pH 7.4 were completed to remove 
any excess dextran from the sample. Fixation and staining followed. Due to the 
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free lysines present in the dextran molecules, treatment with 10% formalin fixed 
the dextran molecules in place.  
 
VE-Cadherin  & hCD31 Staining 
Constructs were stained for either VE-cadherin or human CD31. After the 
constructs were allowed to incubate for a specified time period (3, 5, 7, 10, 12, or 
14 days), samples were fixed in 10% formalin (Sigma Aldrich) at 4°C for 20 
minutes. Formalin was removed with three 5 minute washes in PBS. Cell 
membranes were permeabilized with 0.25% Triton X-100 in TBS-T for 5 minutes. 
Non-specific protein binding was eliminated with a 1 hour block in antibody 
diluting solution (0.1% Triton X-100 in TBS (TBS-T), with 2% bovine serum 
 
  
 
Fibrinogen 
HUVEC-Coated 
Microcarrier Beads 
 
 
Fibrinogen 
 
+ Thrombin 
Fibroblasts 
 
  
 
  EGM-2 
 
Figure 3.2 Schematic diagram of tissue construct assembly. HUVEC-coated microcarrier beads are 
suspended in a solution of fibrinogen and thrombin which forms a fibrin clot. A layer of fibroblasts was 
plated on top of the gel to provide pro-angiogenic cues that induce capillary sprout formation.  
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albumin) (AbDil), and then washing was repeated 3 times with TBS-T. Human 
VE-cadherin primary antibody (BV9 clone, Santa Cruz Biotechnology, Santa 
Cruz, CA) was diluted 1:50 in AbDil and incubated at 4°C overnight. After 
incubation, excess antibody was removed with 3 washes in TBS-T of 20 minutes 
each, and then a final overnight wash. Secondary antibody (AlexaFluor 488 goat 
anti-mouse, Invitrogen) at a 1:100 dilution in Abdil was incubated for 2 hours. 
Excess antibody was removed with 3 washes in TBS-T of 20 minutes each and 
then a final overnight wash at 4°C. Cells were also stained with DAPI nuclear 
stain (Invitrogen) at a 1:10,000 dilution in PBS for 10 minutes and washed for 10 
minutes.  
For human CD31 staining, the process was similar, with the following 
exceptions. The permeabilization step was omitted. Human CD-31 primary 
antibody (Dako, Carpinteria, CA) was diluted 1:50 in AbDil and incubated at 4°C 
overnight. All subsequent steps were as described above for VE-cadherin 
staining, with the exception of a secondary antibody concentration of 1:400.  
 
Design of an Image Analysis Program for Quantification 
A customized MATLAB algorithm was designed to quantify the amount of 
dextran that was able to penetrate into the capillaries. All acquired confocal z- 
stacks were overlayed and compiled into a 3D overlay of the images of each as 
shown in Figure 3.3, Panel A. A 100-by-100 pixel box was placed in this image to 
read the background level of green. Each green image from the 3D z-stack is 
then seen in gray scale (Panel B). The maximum projection of these green 
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images from the z-stack is converted to a binary image. The cutoff for this binary 
image is the background level which was previously defined in Panel A. The 
portion of the red 3D z-stack that lies within the green image is seen in Panel D 
as a gray scale maximum projection image. In Panel E, only pixels from the red 
image in Panel D that overlap with the image in Panel C are shown. The pixel 
intensities from the image in Panel E are then tallied and the output as a ratio of 
red:green.  
 
Grayscale of red 
image 
Red levels within  
the green binary 
E
Composite for 
background levels 
Grayscale of        
green image 
Binary of green   
image to compute red 
CBA
D
Figure 3.3. Pixel comparison algorithm. In Panel A, the algorithm makes a 3D overlay of the images of 
each channel. The user defines the location of a background box. In Panel B, each green image from the 
3D z-stack is depicted in gray scale. In Panel C, the maximum projection of the green z-stack is 
converted to a binary image after the background (defined in Panel A) is eliminated. In Panel D, the 
portion of the red 3D z-stack that corresponds to the same area depicted in the green image is shown in 
gray scale as a maximum projection. In Panel E, only those pixels from the red image in Panel D that 
overlap with the green pixels in Panel C are shown. The pixel intensities from the image in Panel E are 
tallied and output as a ratio of red:green. 
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Figure 3.4. Brightfield 4x images of 3D fibrin gels with a single microcarrier 
bead imaged for days 0, 1, 3, and 7 after seeding. By day 7, a robust 
capillary network is seen.  
Statistical Analysis 
All statistical analyses were performed using GraphPad Prism (GraphPad 
Software, La Jolla, California). Data are reported as mean ± standard deviation. 
One way analysis of variance (ANOVA) was performed with a Newman-Keuls 
multiple comparison post-hoc test. Statistical significance was assumed when p < 
0.05.  
3.3 Results 
A. Reproduction of 3D Angiogenesis Tissue Culture Model 
A 3D model of in vitro angiogenesis using HUVECs and fibroblasts was 
reproduced following a previously established protocol.(13) Briefly, HUVECs 
were seeded on 
microcarrier beads 
and embedded in 
fibrin gels with 
fibroblasts 
distributed 
throughout the gels 
(See Figure 3.4). At 
early time points, the 
HUVECs were 
coated on the 
microcarrier bead and 
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Figure 3.5. VE-Cadherin and DAPI staining of 
confluent monolayer of HUVECs to illustrate 
cell-cell junctions formed between cells to 
modulate permeability.  
fibroblasts were observed as small, round cells within the gel. At later time points, 
the HUVECs migrated off of the bead into tubular structures and fibroblasts 
stretched into long, thin cells throughout the gel. Based on prior studies, it was 
also expected that some fibroblasts are colocalizing with the nascent capillary 
sprouts and adopting a pericytic phenotype.(14)  
B. 2D VE-Cadherin Staining 
Vascular endothelial cadherin, also known as Cadherin 5, is an encoded 
calcium-dependent glycoprotein that links neighboring endothelial cells (ECs). 
These junctions are known to modulate permeability between aligned ECs, so 
visualization of these junctions may assist in defining the varying degrees of 
permeability for each sample and experimental condition. Confluent monolayers 
of HUVECs were cultured, fixed, and stained using an antibody that binds to VE-
cadherin junctions (See Figure 3.5). This method was applied to visualize cell-
cell junctions during capillary sprouting and morphogenesis.  
C. 3D Imaging of Angiogenesis Model 
A 3D model of in vitro angiogenesis 
was reproduced as described in Section 
3.2, and capillary sprouts were imaged 
using 3D confocal microscopy to visualize 
the cell-cell junctions stained with a VE-
cadherin antibody as described above (See 
Figure 3.6). To characterize the permeability and maturation of these capillary 
sprouts, fluorescent dextran was added to the culture medium. At early time 
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Day 7 Day 10 
Day 12 Day 14 
Figure 3.6. VE-Cadherin staining 
and dextran permeability assay. 
20x images of capillary sprouts 
off of microcarrier beads in 3D 
fibrin gels. Samples were treated 
with a dextran tracer  (red) within 
the gel, and then were fixed and 
stained for VE-cadherin (green) 
and DAPI (blue).  
Day 5 
points (day 5), the concentration of dextran within each capillary sprout was a 
qualitative indication of the immaturity of the nascent vessels. As the sprouts 
matured, the junctions between cells became more prominent and started to 
control permeability into the sprouts, qualitatively reducing the amount of 
fluorescent dextran that could diffuse from the bulk tissue into the lumens of the 
capillaries. There were still low levels of dextran detected within the vessels at 
days 7 and 10, but as the cultures matured further, the dextran was nearly 
completely excluded from the lumens of the capillaries. However, these images 
revealed a new challenge, as it was difficult to use a vascular endothelial 
cadherin antibody to image immature vessels that had yet to form competent 
cell-cell connections, or vessels where the cell-cell junctions did not fall in a 
single focal plane as they matured and grew larger.   
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Day 5 
Day 10 
Figure 3.7. Model thickness testing images. 20x images of capillary sprouts 
off of microcarrier beads in gels of 125 μl (left) and 150 μl (right) at days 5 
and 10. Samples were treated with a dextran tracer (red) within the gels, and 
then were fixed and stained for phalloidin (green) and DAPI (blue).  
D. Gel Thickness Optimization for Confocal Microscopy 
To facilitate imaging of the capillary structures within the thick 3D cultures, 
thinner gels were constructed and imaged as maximum projects of 3D vertical z-
stacks using confocal microscopy. Gel volumes of 125 and 150 μl were 
constructed, with resulting gel thicknesses of 1.79 and 2.14 mm, respectively. To 
visualize the vessels even at an early stage prior to functional cell-cell junction 
formation, phalloidin was used to stain the actin filaments of all cells. In Figure 
3.7, the thicker gels inhibited clear imaging and resulted in hazy images with a 
high degree of background noise. This noise interfered with proper processing of 
the images and 
quantification of 
the amount of 
dextran within 
each capillary. 
Therefore, gels of 
125 μl each were 
used for all future 
in vitro 
experiments. 
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E. Live Capillary Perfusion Assay in vitro 
Prior to constructing the tissues, HUVECs were first infected with GFP to 
allow for immediate live cell imaging during the assay, rather than requiring 
fixation and staining to visualize the capillary structures. At each time point, gels 
were incubated in the fluorescently conjugated dextran tracer solution. The 
capillary sprouts were found to gradually mature, with less and less dextran 
transport through the endothelium over time. Prior to day 5 of growth, the tracer 
easily penetrated through the vessel walls and permeability was high (Figure 
3.8). After day 5, dextran accumulated at the periphery of the vessel, with very 
little transport across the endothelium. This can be clearly seen in Figure 3.9, the 
quantification of the images from Figure 3.8. Days 3 and 5 produced significantly 
higher levels of fluorescence within the capillaries than days 7, 10, 12, and 14 (p 
< 0.05). Days 7 and 10 excluded a significant amount of the tracer, and days 12 
and 14 resulted in even lower levels of tracer in the capillary lumens. This result 
shows a clear transition from the initial permeable sprouting phase to a mature, 
stable, selectively-permeable phase of capillary growth that has shut out the high 
molecular weight dextran conjugates with a known diameter of 12 nm. Because 
the dextran was in suspension throughout the gel (not fixed to the fibrin), the 
challenge with these images was to distinguish where the tracer was 
concentrating, either at the interior or exterior of each capillary.  
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Day 3 Day 5 Day 7 
Day 12 Day 14 Day 10 
Figure 3.8 Live cell imaging with dextran tracing. 20x images of live GFP-labeled HUVEC capillary 
sprouts at varying days of growth. During early growth, there are many short, thin sprouts with dextran 
throughout the structure. At later time points, sprouts are highly branched, thicker, and more stable.   
 
 
 
 
 
 
 
 
 
 
 
 
F. Fixed Capillary Perfusion Assay in vitro 
In order to eliminate some of the background noise in the live cell imaging, 
samples were fixed. This allowed for the free lysines on the dextran molecules to 
crosslink to the fibrin matrix and remove excess tracer. Samples were stained for 
human CD31, a known molecular marker of endothelial cells. DAPI, a fluorescent 
stain that binds to DNA, was used as a nuclear marker. The same trend was 
seen in these images as was seen in the live cell imaging; however, the tracking 
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Figure 3.9. Quantification of live-cell imaging with 
dextran tracing. It can be seen that there are 3 
significantly different groupings of fluorescence, with 
the highest levels of dextran within the vessels at 
early time points, and much less dextran 
accumulating within the vessels at later time points, 
once the vessels have matured.  
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of dextran concentration was much more easily visualized with these fixed 
samples. The drawback to this type of imaging was the loss of some of the 
fluorescent dextran, as the molecules are fixed and any tracer that was not 
cross-linked to the matrix is washed away. In Figure 3.10, at early time points, it 
can be seen that dextran concentrated within the capillary sprouts (days 3-5), 
while at later time points (days 12-14), the vessels are more mature and were 
able to keep the tracer from crossing the endothelium and accumulating in the 
lumen. For quantification of the images from Figure 3.10, see Figure 3.11.  
3.4 Discussion 
 
 Capillary functionality is a key component of the developing tissue 
engineering community. Several groups have effectively used fluorescent tracers 
of various molecular weights as indicators of capillary permeability. (9) These 
dextran molecules function as would any molecular components of the blood, 
which would need to effectively diffuse through the endothelial layer in 
capillaries.(12) Other groups have previously used microfluidics or transwells 
with endothelial monolayer cultures to measure transendothelial resistance and 
permeability; however, these are not effective measures of trans-capillary 
permeability in situ. (15)  
 As discussed throughout the results section, several hurdles needed to be 
overcome to successfully develop an assay that is able to detect permeability 
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changes in our established 3D in vitro model of capillary morphogenesis. First, 
the cell-cell junctions between endothelial cells were imaged. This was done in 
an effort to see how these junctional connections control permeability, and to 
chart the development of these permeability-controlling complexes. However, the 
challenge with this method was that the appearance of these junctional 
complexes was a time-dependent process. At early time points, there was a 
sparse level of expression, thus causing fluorescent imaging and determination 
of the capillary periphery to be difficult. At later time points, this became an easier 
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Figure 3.11. Quantification of fixed cell imaging 
with dextran tracing. It can be seen that there 
are 3 significantly different groupings of 
fluorescence, with the highest levels of dextran 
within the vessels at early time points, and much 
less dextran accumulating within the vessels at 
later time points, once the vessels have 
matured. The trend is the same as in Figure 3.9, 
with lower absolute values due to the fixation of 
dextran.  
Figure 3.10. Fixed cell imaging with dextran tracing. 20x images of fixed CD-31 labeled HUVEC 
capillary sprouts (green) at varying days of growth. During early growth, there are many short, thin 
sprouts with dextran (red) throughout the structure. At later time points, sprouts are highly branched 
and more stable, with dextran accumulating only at the vessel periphery.  
Day 3 Day 5 Day 7 
Day 12 Day 14 Day 10 
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task; however, 3D reconstruction of capillary tubules using confocal microscopy 
with VE-cadherin fluorescent staining was still difficult, owing to the sparseness 
of the complexes. Due to the 3D nature of this system, staining could appear in 
multiple focal planes and was difficult to discern the distinct edges of each 
capillary. This problem was exacerbated when capillaries did not grow parallel to 
the bottom of the plate. Because of this, broad-spectrum staining via a known 
positive marker of the endothelial cells, CD31, was used to mark capillary 
borders for quantification purposes.  
 The thickness of the 3D gels was known to have an effect on capillary 
growth, as was previously determined.(11) Gels were scaled down across all 
dimensions, in order to eliminate the excessive background noise due to freely 
diffusing dextran throughout the gels during confocal imaging. Two different gel 
thicknesses were tested in order to achieve optimal imaging with the thickest 
possible gels, to most closely mimic previous work and physiological conditions. 
Thinner gels more closely approximate 2D growth conditions than 3D conditions, 
so thicker gels were desired.  
 Both live imaging with GFP-tagged endothelial cells, and imaging after 
fixation with human CD31 stained endothelial cells was done to ensure that the 
trend observed was due to the maturation kinetics of the capillaries rather than 
being an artifact of the staining assay. The same trend was observed with both 
modalities; thus, the maturation rates of the capillaries were determined to be the 
varying condition. Fixation of the cultures allowed the dextran to be much less 
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overpowering in the culture system, and the imaging became much clearer. For 
all future experiments, fixed cultures were used.  
 Three distinct phases of capillary maturation were seen in these results, 
aligning with the previous descriptions of the angiogenic process. Initially, there 
was a phase where the capillaries were still sprouting and developing into 
tubules, few cell-cell junctions were observed, and little control over permeability 
was observed. Next, there was a mid-phase, where cell-cell junctional complexes 
are beginning to appear, and the capillaries are starting to have some level of 
functional control. Finally, there was a phase of stabilized, mature capillary 
functionality, where the sprouts were able to exclude most of the tracer from their 
lumens.  
 In summary, the experimental processes discussed in this chapter helped 
to achieve a robust assay. This assay was then used for comparisons of growth 
kinetics across several stromal cell types, and was then adapted for use on in 
vivo samples as well.  
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CHAPTER 4 
Functionality Comparisons Across Cell Types in a 3D Co-Culture 
of Engineered Capillaries 
 
4.1 Introduction 
 
Success within the tissue engineering field continues to be limited due to 
the inability to form a functional vasculature capable of supplying oxygen and 
nutrients to sustain tissue growth and metabolism.(1-3) Fabrication of constructs 
larger than 200 μm in thickness has been mostly unsuccessful, with large, hollow 
organs or avascular tissues being two exceptions.(4) Tissues thicker than this 
threshold are unable to overcome the limits of diffusion to properly nourish the 
tissue. Several possible solutions to overcome this hurdle have been proposed 
and explored in the literature over the past decade. One promising option 
involves the delivery of combinations of pro-angiogenic factors with precise 
spatial and temporal resolution in order to recruit host vasculature.(5) However, 
this approach can be limited by the fact that the half-lives of these factors are 
often very short, thereby limiting their bioactivity, and by the fact that even 
multiple combinations of factors cannot fully recapitulate the complex milieu of 
pro-angiogenic factors presented to cells in vivo.  An alternative approach is to 
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provide the cell types that are required for new vessel formation, so that they can 
directly deliver the appropriate cocktail of required pro-angiogenic cues as 
necessary. Amongst the most recent possible solutions to overcome this hurdle 
is the idea of creating prevascularized tissues, which contain networks of vessels 
formed in vitro that can self-organize and anastamose with the host vasculature 
in vivo shortly after implantation.(6, 7) 
Efforts to create prevascularized tissue constructs typically involve co-
cultures of ECs and a supporting mesenchymal cell type, which is intended to act 
as a pericyte coat, within a 3D biomaterial scaffold.(8, 9) Several cell types have 
been shown to promote capillary morphogenesis and adopt periendothelial 
locations, including fibroblasts(10), SMCs(11), MSCs(12), and AdSCs.(13, 14) 
While all of these cell types appear to promote capillary formation,  it is unclear if 
each type yields capillaries whose functional properties are similar to those of 
healthy, mature capillaries. Previous work from our group shows that different 
stromal cells promote capillary sprouting in fibrin hydrogels via different 
proteolytic enzymes(15-17), but the functional consequences (if any) of this 
difference are unknown.  
This study focuses on the functional differences of capillary networks 
assembled from ECs and these varying mesenchymal cell types as stabilizing 
pericytes, using permeability as one marker of vessel functionality. A model of 
inverse permeability was developed, as was described in Chapter 3. Junctional 
staining and Western blotting were done to further explore the mechanisms of 
permeability control and pericyte differentiation as well.  
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4.2 Methods 
Ethics Statement 
Human umbilical vein ECs (HUVECs) were harvested from fresh umbilical 
cords following a previously established protocol.(8) The cords were obtained via 
a process considered exempt by the University of Michigan’s institutional review 
board because the tissue is normally discarded, and no identifying information is 
provided to the researchers who receive the cords. 
 
Cell Culture 
HUVECs were grown in fully supplemented Endothelial Growth Medium 
(EGM-2, Lonza, Walkersville, MD). Normal human lung fibroblasts (NHLFs, 
Lonza) were cultured in Media 199 (Invitrogen, Carlsbad, CA) supplemented with 
10% FBS, 1% penicillin/streptomycin (Mediatech, Manassas, VA), and 0.5% 
gentamicin (Invitrogen) at 37°C and 5% CO2. Mesenchymal stem cells (Lonza) 
and adipose-derived stem cells (Invitrogen) were cultured in Dulbecco’s modified 
Eagle Medium (DMEM, Sigma-Aldrich, St. Louis, MO) supplemented with 10% 
FBS, 1% penicillin/streptomycin (Mediatech), 0.5% gentamicin (Invitrogen) at 
37°C and 5% CO2. NHLFs, MSCs, and AdSCs were all used prior to passage 
ten.  Cells were cultured in monolayers until reaching 80% confluency and 
serially passaged using 0.05% trypsin-EDTA treatment.  
 
Tissue Construct Assembly 
Constructs were made as described in detail in Chapter 3. Identical 
constructs were also made using AdSCs and MSCs. For some applications, 
94 
stromal cells were distributed throughout the gel constructs rather than in a 
monolayer on top of the constructs.  
 
Tissue Construct Assembly for Confocal Microscopy 
The modified protocol was followed as described in Chapter 3. In short, 
small scale gels of 125 μl total volume of a 2.5 mg/ml fibrin solution were 
constructed in each well of an 8-well chambered #1 coverglass. Gels contained 
25 pre-coated endothelial cell-Cytodex beads, and 10,000 stromal cells (either 
NHLFs, MSCs, or AdSCs) were distributed throughout the matrix.  
 
Permeability Assay 
Selectively permeable mature capillaries are known to be impermeable to 
dextrans over a molecular weight of 65 kDa, so a Texas Red-conjugated dextran 
(λex/em of 595/615 nm) with a molecular weight of 70 kDa was chosen 
(Invitrogen).(23) This dextran molecule also contains free lysines, and is 
therefore fixable in formalin. All samples were directly incubated at 25°C for 30 
minutes with a 5% dextran solution in phosphate buffered saline (PBS), and then 
excess dextran was removed by 3 washes of 10 minutes each with PBS. In some 
experiments, histamine (Sigma-Aldrich) was added to capillary cultures prior to 
dextran addition and culture termination via fixation at a concentration of 100 μM 
and allowed to incubate for 5 minutes.(22) Assays were continued as previously 
described above by addition of dextran, fixation, staining, and 3D confocal 
imaging.  
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Staining 
All VE-cadherin and human CD31 staining was done following the 
protocols described in Chapter 3.  
 
Western Blotting 
After the constructs were allowed to incubate for a specified time period 
(3, 5, 7, 10, 12, or 14 days), samples were lysed using RIPA lysis buffer (50 mM 
Tris-HCl pH 7.6, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 
0.1% SDS), homogenized, and two cycles of 30 second sonication and 20 
second vortexing were completed. Lysates were cleared via centrifugation at 
14,000 x g for 10 minutes at 4°C. Total protein concentration was determined via 
bicinchoninic acid assay (Thermo Fisher Scientific, Waltham, MA). Samples were 
boiled, then equal amounts of total protein were loaded for all co-culture 
conditions into a 10% tris-glycine gel (Invitrogen) and then electrophoretically 
separated for 3.5 hours. Proteins were then transferred onto a poly(vinylidine 
fluoride) membrane and probed via mouse anti-human VE-cadherin antibody 
(Santa Cruz Biotechnology). After washing, secondary horseradish peroxidase-
conjugated anti-mouse antibody was incubated on the membrane (Santa Cruz 
Biotechnology). Protein expression was then visualized via an enhanced 
chemiluminescence detection system.  
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Quantification of Total Network Length & Number of Vessel Segments 
Prior to bead coating, HUVECs were labeled with cell tracker dye, SP-
DiIC18(3) (Invitrogen) and tissues were constructed as described above. Low 
magnification fluorescent images (4x) were taken at days 3, 7, 10, and 14 by 
tracking the same beads throughout growth via MetaMorph (Molecular Devices, 
Sunnyvale, CA). Images were then quantified via the Angiogenesis Tube 
Formation module of MetaMorph to track the total network length and the total 
number of vessel segments per bead. Upper and lower limits were defined to 
exclude beads and nodes from the quantification. Five individual beads were 
imaged per cell type for each of three separate experiments for a total of fifteen 
images per experimental condition.  
 
Confocal Microscopy 
Thin tissue samples were made as described in Chapter 3, incubated for 
desired time periods, and a dextran assay was done as described earlier. All 
samples were imaged using an Olympus IX81 spinning disk confocal microscope 
equipped with a 100-W high pressure mercury lamp (Olympus, Center Valley, 
PA) and a Hammamatsu camera (Bridgewater, NJ) along a vertical z-stack of the 
entire diameter of each capillary with 0.5 μm optical slices to visualize the 
location of dextran within the interior/exterior of each capillary. Each set of 
images was quantified using the methods described in Chapter 3. Single 
confocal images were taken for proof of concept dextran localization on a Zeiss 
LSM 510-Meta laser scanning confocal microscope.  
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Statistical Analysis 
All statistical analyses were performed using GraphPad Prism (GraphPad 
Software, La Jolla, California). Data are reported as mean ± standard deviation. 
One way analysis of variance was performed with a Newman-Keuls multiple 
comparison post-hoc test. Statistical significance was assumed when p < 0.05.  
4.3 Results 
A. Assay Development and Validation 
During angiogenesis, new capillary sprouts form following initial budding 
from a source vessel, and become more elongated, branched, and stabilized by 
supporting pericytes over time. An important functional hallmark of new 
capillaries is the reformation of basement membrane and the ability to regulate 
transport across the vessel wall. In this study, a 3D cell culture model of 
angiogenesis was combined with a quantitative algorithm to develop a metric of 
capillary permeability and maturation. At specific time points, fluorescent dextran 
was added to the culture medium and allowed to incubate for a short period of 
time, after which the cultures were fixed. The localization of the dextran on the 
inside or outside of the capillary also provided an indirect determination of the 
timing of pericyte-EC associations. To better define the edges of capillaries for 
our quantitative algorithm, HUVECs that sprouted from the microcarrier beads 
were also stained with hCD31 antibodies. 
Within the first few days after the 3D cell culture was initiated, HUVECs 
coated on the microcarrier beads began to sprout.  At relatively early time points 
(day 5), dextran tracer added to the culture medium permeated throughout the 
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entire 3D gel, and could even be found within the newly-formed lumens of the 
nascent vessels (Figure 4.1A), consistent with the idea that these vessels are 
particularly immature and lack the structural features necessary to regulate 
permeability.  As the sprouts matured, dextran transport across the vessel wall 
was limited as shown by the reduced amount of fluorescent dextran that diffused 
from the bulk tissue into the lumens of the capillaries. As the cultures matured 
further (day 10), the dextran was nearly completely excluded from the lumens of 
the capillaries (Figure 4.3B), especially as seen in cross-section (Figure 4.1B, 
inset).  
To validate this model system and our quantitative algorithm, cultures 
were treated with histamine, a known modulator of capillary permeability.(22, 24) 
The output of the quantitative algorithm was a ratio of red (dextran) to green 
Figure 4.1. Dextran tracer localization via confocal microscopy. 60x confocal microscopy images of days 5 
(A) and 10 (B) capillaries after 70 kDa dextran tracer addition (red), fixation with 10% formalin, and human 
CD31 staining (green) of HUVECs. Inset images: HUVECs (top) and Dextran (bottom) show hollow 
lumens with or without dextran. A) Red tracer is present within the lumens of the capillaries, demonstrating 
a low resistance to permeability. B) Red tracer is excluded from the lumens of the capillaries, 
demonstrating an increased resistance to permeability as the capillaries mature over time. 
No red 
dextran in 
the lumen 
Red dextran 
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(CD31) fluorescence for each capillary.  After treatment with histamine, cultures 
showed a marked increase in permeability across all time points (Figure 4.2). At 
day 3, histamine triggered a 39% increase in permeability over untreated 
controls, even though the vessels were relatively immature in terms of their 
structure. By day 14, when the vessels had fully matured, tracer accumulation 
within the capillaries following histamine treatment was nearly twice that of 
untreated controls, indicating that the nascent capillaries are indeed capable of 
regulating their permeability in response to a physiologic stimulus, and that our 
algorithm is capable of detecting such changes. 
 
B. Control of Permeability Evolves as Capillaries Mature 
Next, we used this newly validated approach to characterize the kinetics 
with which the capillaries formed within our 3D cell culture model as it matures 
over time. The baseline model system involves the use of stromal fibroblasts 
(i.e., NHLFs) distributed throughout the 3D gels as the source of stabilizing 
pericytes. At early time points (days 3 and 5), dextran tracer accumulated within 
the lumens of capillaries, as shown by the high ratio of red (dextran) to green (the 
boundary of the capillaries, marked by hCD31 staining) fluorescence (Figure 4.3, 
solid gray bars). These high levels of permeability gradually decreased with time 
as the capillaries matured. At intermediate time points (days 7 and 10), the 
red:green ratio decreased by up to 48% when fibroblasts were used as the 
stromal cells (Figure 4.3, black bars). By later time points (days 12 and 14), 
almost all of the  
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dextran was being excluded from the capillary lumens (89% decrease from initial 
levels).  
 
C. Alteration of Stromal Cell Type Modulates Capillary Permeability 
When stromal cell types other than fibroblasts were used to stimulate 
capillary morphogenesis in this assay, we observed significant differences in the 
regulation of vessel permeability. Specifically, MSCs and AdSCs produced stable 
capillaries much more quickly than did the fibroblasts, as shown by a significant 
reduction in the ratio of red to green fluorescence (Figure 4.3, white and 
crosshatched bars).  At day 3, capillaries composed of HUVEC-MSC co-cultures 
and HUVEC-AdSC co-cultures showed reductions in red to green fluorescence of 
50 and 59%, respectively, compared to the values from HUVEC-fibroblast co-
cultures.  This indicated that far less of the dextran tracer crossed the capillary 
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Figure 4.2. Assay validation using histamine to modulate capillary permeability. Histamine treatment 
quantitatively modulates permeability of the engineered capillary networks, as expected. In this graph, 
the * symbol indicates statistical significance (p<0.05) between the black and white bars (-/+ 
histamine) at each time point. The +, #, and % symbols indicate statistically significant differences 
(p<0.005) between the data marked by these symbols at certain time points and all other time points 
marked with different symbols. For example, the values at day 3 and day 5 (for both -/+ histamine) are 
significantly different from the values at all of the other time points, but not from each other. 
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walls in cultures containing these multipotent stromal cells compared to those 
containing fibroblasts. At later time points, these capillaries also regulated their 
permeability much more tightly than their fibroblast counterparts, with highly 
significant decreases of 68% and 77% in the red:green fluorescence ratios by 
day 14 for the MSC-mediated capillaries and the AdSC-mediated capillaries, 
respectively, relative to the fibroblast controls.  
To better understand mechanistically how permeability might be 
differentially controlled by each stromal cell type, the protein levels and 
organization of VE-cadherin were assessed. Immunofluorescent staining of VE-
cadherin revealed that the cell-cell junctions between neighboring endothelial 
cells of capillary sprouts were more pronounced in EC-AdSC and EC-MSC co-
cultures, whereas the EC-NHLF co-cultures showed evidence for more sparse 
EC-EC junctions (Figure 4.4, Panels A-C). Co-cultures containing stem cells also 
possessed elevated levels of VE-cadherin protein via Western blotting (Figure 
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Figure 4.3. Quantification of permeability using a customized algorithm. Quantification generated 
via the customized MATLAB algorithm to determine the amount of Texas Red-conjugated dextran within 
the capillary interior at each time point. An isolated * symbol indicates statistical significance (p<0.05) 
between data points (NHLF vs. MSC vs. AdSC) at any one particular time point, whereas a bar beneath 
the * symbol indicates statistical significance (p<0.05) across all 3 experimental groups at each time 
point. The +, #, and % symbols indicate statistically significant differences (p<0.005) between the data 
marked by these symbols at certain time points and all other time points marked with different symbols. 
102 
4.4, Panel D). When ECs were omitted from the cultures, the MSCs produced 
positive levels of VE-cadherin via Western blotting, while the AdSCs and NHLFs 
were less able to modulate and express vascular markers without ECs in co-
culture.  
D. Expression of Stromal Cell Markers Modulates in 3D Culture 
 Western blotting for alpha smooth muscle actin (α-SMA) shows positive 
staining for all three stromal cell types when cultured in a 2D monolayer culture; 
however, once placed in 3D, these values change (Figure 4.5). The MSCs 
express less α-SMA in 3D when co-cultured with ECs, and express no detectable 
α-SMA when cultured alone in 3D. The AdSCs also attempt to modulate away 
from this myofibroblastic phenotype when co-cultured with ECs in 3D, while the 
NHLFs produce positive bands both with and without ECs in co-culture. 
Calponin, a mature smooth muscle marker, produces no positive bands for any 
culture conditions after 14 days. Together, these data indicate that the stem cells 
in co-culture are migrating toward a pericytic phenotype, while fibroblasts are not 
adopting this shift. 
 
E. Stem Cells Produce Slower Growth Kinetics  
Prior work has shown that the presence of stromal cells is required for 
capillary morphogenesis(25); however, the results presented here indicate that 
the identity of the stromal cells may also significantly impact the functional 
properties of the vessel networks. We hypothesized that these observed 
differences in vessel functionalities may be related to the rates at which the 
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 vessel networks form. To further explore this possibility, the kinetics of capillary 
growth were assessed as a function of stromal cell identity (i.e., NHLF vs. MSC 
vs. AdSC) and their location relative to the capillaries (i.e., as a monolayer a fixed 
distance away from the HUVECs vs. distributed throughout the 3D gel) (Figure 
4.6). When cultured as monolayers a fixed distance above the HUVEC-coated 
beads, AdSCs and MSCs produced capillary networks that were only 47 and 
56% of the total lengths of the capillary networks induced by monolayer fibroblast 
Figure 4.4. VE-cadherin organization and expression vary as a function of stromal cell type. A-C) 20x 
confocal microscopy images of day 14 capillaries from co-cultures of EC-NHLF (A), EC-AdSC (B), and EC-
MSC (C) after staining for VE-cadherin (green) and DAPI (blue). D) Western blot showing expression of 
VE-cadherin within each of the stromal cell conditions, in 2D and 3D. 
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cultures (Figure 4.6D). When stromal cells were distributed throughout the fibrin 
gels to more closely approximate physiologic conditions, total network lengths 
increased for all stromal cell types in comparison to constructs in monolayer 
cultures; however, a similar trend was seen where cultures with stem cells
produced networks with much shorter total lengths than those capillaries cultured 
A 
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23 kda 
α-SMA 
        MSC/AdSC/NHLF  MSC/AdSC/NHLF  MSC/AdSC/NHLF 
(-EC,2D) (-EC,3D) (+EC,3D) 
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Figure 4.5. α-SMA expression varies as a function of stromal cell type and culture condition, while 
calponin is not expressed in 2D or 3D cultures. A) Western blot showing expression of α-SMA in 3D with 
ECs, in 3D without ECs, and in 2D without ECs. B) Western blot showing a lack of expression of 
calponin within each of the same culture conditions as in (A).  
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with NHLFs as a source of stromal cells. AdSC and MSC capillary cultures 
produced only 43 and 45% of the total network length of fibroblast cultures after 
14 days of growth (p < 0.005) (Figure 4.6D).  
To further characterize how the identity of the stromal cells affected 
capillary network growth, the total number of vessel segments per network was 
also quantified (Figure 4.7E). After 14 days, EC-MSC and EC-AdSC co-cultures 
produced averages of 207 and 150 segments per dextran bead, while EC-NHLF 
co-cultures produced fewer segments per network, an average of 111. When 
these values were used in conjunction with total network lengths, EC-NHLF co-
cultures had an average segment length of 463 μm after 14 days of culture, 
whereas EC-MSC and EC-AdSC co-cultures had average segment lengths of 
only 110 μm and 148 μm, respectively. Together, these data demonstrate that 
EC-NHLF co-cultures formed longer, more spindly, and less-branched capillary 
networks than did co-cultures containing either stem cell type. 
4.4 Discussion 
 
Capillaries, composite systems of endothelial cell tubules that are sparsely 
covered with pericytes and a supporting extracellular matrix, serve many 
functions within the body, most notably acting as selectively permeable barriers 
which allow nutrients and oxygen into the surrounding tissues, as well as 
extracting waste products.(26, 27) Larger vessels must also react to vasoactive 
stimuli, tightening or expanding when required, in order to maintain a level blood 
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Figure 4.6. Capillary growth kinetics vary by stromal cell type. A-C) Representative 4x images of 
fluorescently-tagged HUVECs forming capillary networks in co-culture with A) AdSCs, B) MSCs, C) 
NHLFs. D) Comparison of growth kinetics for several stromal cell types in the bead assay. “Mono” 
denotes the stromal cells were cultured as a monolayer on top of the fibrin gel, a fixed distance 
away from the HUVEC-coated beads; “distributed” indicates the stromal cells were distributed 
throughout the entire 3D gel. E) Comparison of the number of vessel segments per network for each 
stromal cell type. The * symbol indicates statistical significance (p<0.05) between time points within 
a given culture condition. The +, #, %, and @ symbols indicate statistical significance (p<0.005) for 
a particular culture condition at a given time point versus the other culture conditions. For example, 
the total lengths of the capillary networks induced by distributed NHLFs are significantly different 
than those induced by the monolayer NHLFs and those induced by all of the other cell types and 
distributions (denoted by #). 
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pressure and to supply oxygenated blood to all organs and tissues, regardless of 
the external conditions.(28) In order for a vessel to be classified as functional, it 
must also differentiate to fit into the proper portion of the hierarchical 
structure.(29) Arteries and arterioles function as a pipeline to deliver oxygen and 
nutrients to tissues that are further away, while capillaries provide large surface 
areas for molecular exchange of gases, nutrients, and wastes within the tissue 
space.(30) Recreating capillary blood vessels remains a limiting hurdle to the 
successful clinical implementation of engineered tissues.(31) 
 In the case of implanted tissue constructs, the presence of functional 
capillary networks has typically been defined by the presence of red blood cells 
within lumen-containing structures on histological sections; however, 
observations of leakiness and edema in vivo have created a need for a more 
quantifiable metric of capillary functionality, beyond the mere presence of red 
blood cells.(6, 28, 31, 32) Furthermore, in diseases such as cancer, phenotypic 
changes in the pericyte coat and its dissociation from the endothelial cell layer, 
have been implicated in alterations in vessel permeability.(18, 33, 34) Studies 
using fluorescent tracers and/or non-invasive imaging methods have enabled 
vessel perfusion and functionality to be assessed in vivo.(21) In vitro, established 
permeability metrics typically measure transendothelial resistance in a Transwell 
system in which endothelial cells are cultured in a 2D monolayer. (35) However, 
comparable approaches to assess vessel functionality in 3D are lacking, which in 
turn creates an inability to determine if a promising approach to either promote or 
inhibit vessel formation will also alter vessel functionality. Classical assays of 
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resistance across a monolayer cannot be easily applied to a 3D system where 
the luminal diameters are less than 20 μm; thus a new approach was required.  
To address this limitation, here we have described an in vitro method for 
measuring changes in permeability in the capillary vessels created in a 
previously established 3D tissue culture model.(8) By quantifying the transport of 
a fluorescent tracer from the tissue space into the vessel lumens, we have 
effectively shown that permeability can be inversely measured by the use of 3D 
confocal microscopy and the design of a customized pixel comparison algorithm. 
The method detected decreases in capillary permeability over time, and showed 
that some stromal cell types are better able than others to promote the formation 
of robust, stable networks after 2 weeks of culture. Higher amounts of fluorescent 
tracer inside the capillary lumens were detected at early time points, which we 
attribute to a lack of competent cell-cell junctions between endothelial cells and 
to the fact that pericytes are not yet stabilizing the capillaries. After the constructs 
are allowed to mature for longer periods of time, and the stromal cells make 
direct contact with the capillary sprouts as we have previously shown(15), a 
direct reduction in the amount of tracer was observed in the capillary lumens.  
The quantitative algorithm developed here demonstrated the capability to 
discern quantifiable differences in permeability induced by histamine, a known 
modulator of permeability, in both immature and mature capillary sprouts.  This 
result is particularly striking given that the lumenal surfaces of neovessels within 
our system are not perfused via fluid, which has been shown to influence 
permeability in other systems.(36) We have also shown here that the use of 
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different stromal cell types in our capillary culture system produces capillaries of 
varying phenotypes and maturation levels as determined both visually and 
quantifiably using our permeability assay.  In recent studies, we have also 
reported that the mechanisms by which endothelial cells proteolytically degrade 
the surrounding matrix to form new capillary tubules depends on the identity of 
the stromal cells in HUVEC-stromal cell co-cultures.(15)  Whether or not these 
mechanistic differences account for the functional differences observed here 
remains to be seen. 
We have typically used fibroblasts as the stromal cell type in our in vitro 
models of angiogenesis with the intent of mimicking the wound healing 
environment.(9)  Fibroblasts are recruited into the wound bed from surrounding 
host tissues in order to facilitate faster healing and regeneration of the 
vasculature. Fibroblasts function quickly to promote granulation tissue formation 
via collagen and fibronectin deposition (37), and their ability to drive capillary 
growth in our model system is consistent with their known roles in wound healing 
in vivo.  However, we observed in this work that fibroblasts promote the formation 
of vessels characterized by a reduced capacity to control permeability, especially 
at early time points, relative to those promoted by multipotent stromal cells. 
Fibroblasts also promoted vessels at a significantly faster rate than MSCs and 
AdSCs in our model, but the resulting vessels were longer, less branched, and 
possessed fewer cell-cell adherens junctions between ECs than those formed 
from co-cultures containing stem cells. Also, α-SMA expression, an indicator of a 
myofibroblastic phenotype, was seen to be downregulated by MSCs in 3D 
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cultures, unlike NHLFs. These observations suggest that the multipotent MSCs 
and AdSCs do in fact modulate their functionalities as pericytes to produce 
capillaries that more closely mimic the physiology of healthy vasculature, with 
more controlled permeabilities due perhaps to an increase in EC-EC adherens 
junctions, while the fibroblasts promote a vasculature more reminiscent of 
pathologic angiogenesis. Therefore, an especially important conclusion with 
respect to promoting the neovascularization of engineered tissues has emerged: 
the choice of which cell type to deliver with endothelial cells to create new 
vasculature may determine in part whether the capillaries are physiologically 
healthy or not.   Explicit studies to address this question in vivo are following. 
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CHAPTER 5 
Stromal Cell Identity Governs the in vivo Functionality of 
Engineered Capillary Networks Formed by Co-Delivery of 
Endothelial Cells and Stromal Cells 
 
5.1 Introduction 
 
  Therapeutic angiogenesis, the process of promoting neovascularization 
and tissue repair via the delivery of pro-angiogenic molecules, has been explored 
as a possible means to treat ischemic diseases(1). However, clinical trials relying 
on bolus injection of individual factors have been disappointing (2), perhaps due 
to the limited half-life of most protein growth factors, the lack of temporal and 
spatial control over growth factor release, and the inability of single factors to 
properly regulate neovascularization (3, 4). Newer strategies involving sustained 
delivery of pro-angiogenic factors or genes from biodegradable scaffolds to 
overcome protein stability issues (5-8), as well as delivery of multiple pro-
angiogenic factors in a time-dependent fashion to mimic the process of natural 
vessel development (4, 9), have been shown to induce formation of vascular 
networks. However even combinations of multiple factors may not fully 
recapitulate the complex mileiu of pro-angiogenic signals presented to cells in 
vivo.  
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 Cell-based therapies have also been explored to more completely mimic the 
cascade of signals needed to promote the formation of stable neovasculature. 
These approaches involve delivering an appropriate cell type(s) that can directly 
differentiate into capillary structures or provide a physiologic mixture of pro-
angiogenic cues to accelerate the recruitment of host vessels. A variety of cell 
types have been shown to form new capillary networks and/or induce collateral 
blood vessel development following implantation in vivo (10-13).  In addition, 
cells have been implanted using a wide range of scaffold materials and 
extracellular matrix proteins to improve cell retention and engraftment (14, 15). 
However, most studies have relied on the presence of red blood cells in lumen-
like structures revealed via histology as the sole metric of vessel functionality. 
 A particular challenge for the tissue engineering community is to induce 
vascularization of ischemic tissues with blood vessels that are functionally 
normal. When vascularization is induced too rapidly, as in tumor angiogenesis, 
ECs do not properly align (16, 17). Blood vessel growth induced by tumor 
expansion often results in abnormal branching and growth patterns, defective 
endothelial wall structures, and an abnormal pericyte coat(18). These abnormal 
characteristics relative to healthy vasculature can lead to capillaries that are 
leaky and unable to properly control permeability, contributing to edema in the 
tissue (19, 20).  In the case of engineered capillary networks, our lab and many 
others have had some previous success inducing capillary growth in both 3D in 
vitro cultures (21) and in vivo subcutaneous implants(22). The results from such 
studies have led to the consensus that co-delivery of ECs and a secondary 
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mesenchymal cell type produces the necessary cues to induce tubular sprouting 
of ECs, and stromal cell differentiation toward a pericytic phenotype(23).  
Despite the consensus of this paradigm, there is virtually no consensus with 
respect to the choice of cells to co-deliver with ECs.  A variety of stromal cell 
types of mesenchymal origins have been explored, including mesenchymal stem 
cells from bone marrow(21, 24, 25) or adiopose tissue (26), fibroblasts from 
human lung (27, 28) and mouse embryos(29), as well as smooth muscle cells 
(30). For a subset of these cell types, our previous studies using in vitro models 
have shown that stromal cell identity underlies differences in the mechanisms by 
which capillaries are formed (24, 31), and in the functional properties of the 
resulting capillaries (32). The goal of this study was to determine if the identity of    
 
Endothelial Cells Stromal Cells Fibrin 
NHLF, AdSC, or MSC 
Figure 5.1. Method to engineer vascular networks in vivo. In this study, EC alone or in combination with 
one of three different types of stromal cells (NHLF, AdSC, or MSC) were injected subcutaneously within 
a fibrin matrix on the dorsal surface of SCID mice. The injected cells form a provisional vascular network 
that inosculates with the systemic circulation, as has been shown in several previous studies. However, 
the choice of stromal cells has varied widely across studies, and their impact on the functional qualities 
of the capillaries produced has not been examined.  The goal of this study was to systematically 
characterize the effects of stromal cell identity on the quantity and functional quality of the resulting 
neovasculature.  
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the stromal cells co-delivered with ECs had any similar consequences on the 
functional properties of engineered capillary networks in vivo (Figure 5.1). Our 
results suggest that the identity of the stromal cells significantly influences the in 
vivo functionality of engineered capillary networks. 
5.2 Methods 
Cell Culture 
 Human umbilical vein endothelial cells (HUVECs, hereafter referred to as 
ECs) were harvested from fresh umbilical cords following a previously 
established protocol (21), and were grown in fully supplemented Endothelial 
Growth Medium (EGM-2, Lonza, Walkersville, MD) at 37°C and 5% CO2. Normal 
human lung fibroblasts (NHLFs, Lonza) were cultured in Media 199 (Invitrogen, 
Carlsbad, CA) supplemented with 10% FBS, 1% penicillin/streptomycin 
(Mediatech, Manassas, VA), and 0.5% gentamicin (Invitrogen). Bone marrow 
mesenchymal stem cells (MSCs, Lonza) and adipose-derived stem cells (AdSCs, 
Invitrogen) were cultured in Dulbecco’s modified Eagle Medium (DMEM, Sigma-
Aldrich, St. Louis, MO) supplemented with 10% FBS, 1% penicillin/streptomycin 
(Mediatech), 0.5% gentamicin (Invitrogen). NHLFs, MSCs, and AdSCs were all 
used prior to passage ten. ECs were used at passage 3. Cells were cultured in 
monolayers until reaching 80% confluency and serially passaged using 0.05% 
trypsin-EDTA treatment.  
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Tissue Construct Implantation 
 Animal procedures were performed in accordance with NIH guidelines for 
laboratory animal usage following a protocol approved by the University of 
Michigan’s Committee on Use and Care of Animals. Male 7-week old C.B.-
17/SCID mice (Taconic Labs, Hudson, NY) were used for all experiments. An 
anesthetic/analgesic drug cocktail of ketamine (95 mg/kg, Fort Dodge Animal 
Health, Fort Dodge, IA), xylazine (9.5 mg/kg, Lloyd Laboratories, Shenandoah, 
IA), and buprenorphine (0.059 mg/kg, Bedford Laboratories, Bedford, OH) was 
delivered to each mouse via intraperitoneal injection. The dorsal flank of each 
mouse was then shaved, sterilized with betadine (Thermo Fisher Scientific, 
Fremont, CA) and wiped down with an alcohol pad prior to implant injection. 
 A 2.5 mg/ml bovine fibrinogen solution (Sigma-Aldrich, St. Louis, MO) was 
made in serum-free EGM-2 and filtered through a 0.22 μm syringe filter. Cell 
mixtures in a 1:1 ratio of EC:stromal cells (either NHLFs, MSCs, or AdSCs) were 
spun down and resuspended in the previously prepared fibrinogen solution at a 
final concentration of 10 million cells/mL, totaling 3 million cells per injection 
sample (300 μl total volume). Immediately prior to injection, 5% fetal bovine 
serum and 6 μl of thrombin solution (50 U/ml, Sigma-Aldrich) were added to 300 
μl of fibrinogen-cell solution. For control samples, 3 million ECs without any 
stromal cell type were used. Acellular controls containing fibrinogen, FBS, and 
thrombin were also included. Solutions were immediately injected 
subcutaneously on the dorsal flank of the mouse, with two implants per animal. 
Animals were kept stationary for 5 minutes to allow for implant polymerization, 
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and were then placed in fresh cages for recovery. Five replicates of each sample 
type were completed (EC-NHLF, EC-MSC, EC-AdSC, EC only, and acellular). 
 
Non-invasive Laser Doppler Perfusion Imaging 
At days 3, 7, 10, and 14, mice were anesthetized using the cocktail described 
above, and then subjected to laser Doppler perfusion imaging (LDPI) (Perimed 
AB, Sweden). Each mouse was imaged in triplicate. Results are reported as folds 
increased in relative perfusion units over untreated controls.  
 
Tracer Injection & Implant Removal 
Mature capillaries function as selectively permeable membranes and are 
known to be impermeable to dextrans over a molecular weight of 65 kDa (33). 
Therefore, a Texas Red-conjugated dextran (λex/em of 595/615 nm, Invitrogen) 
was chosen as a functionally-defining tracer. This dextran molecule, containing 
free lysines, is fixable in 4% PFA. At each retrieval time point, final LDPI was 
completed, each mouse was placed in a restraint device, and 200 μl of a 5% 
dextran solution in PBS was then injected via the tail vein. After injection, mice 
were placed into fresh cages and the tracer was allowed to circulate systemically 
for 10 minutes. Animals were then euthanized and implants, including the 
surrounding skin and muscle layers, were surgically excised. 
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Whole-Mount Live Imaging 
Explants were placed onto Petri dishes after removal and immediately 
imaged using an Olympus IX81 spinning disk confocal microscope (Olympus, 
Center Valley, PA) with both a Hammamatsu (Bridgewater, NJ) camera for 
visualization of the fluorescent dextran tracer (Supplementary Figure 1), and a 
DP2-Twain (Olympus) camera for color brightfield images. Macroscopic images 
were taken using a Kodak EasyShare Z1015 IS camera (Kodak, Rochester, NY). 
 
Histology & Immunohistochemistry 
For histology and immunohistochemical staining, explants were fixed in 
4% PFA for 1 hour, 0.4% PFA overnight, then transferred to a PBS pH 7.4 
solution, all at 4°C. All samples were forwarded to AML Laboratories (Baltimore, 
MD) for sectioning. Samples were embedded in paraffin by AML, and then 
sectioned in 5 μm sections and stained with hematoxylin and eosin (H&E) 
according to standard protocols. Immunohistochemical staining of hCD31, α-
smooth muscle actin, and calponin was performed in our laboratory on unstained 
serial sections provided by AML.  Paraffin sections were rehydrated according to 
standard protocol(22), then steamed in a vegetable steamer for 25 minutes in 
antigen retrieval solution (Dako, Carpinteria, CA). Slides were equilibrated in 
TBS-T, and then all subsequent staining was done using a Dako EnVision 
System-HRP (DAB) kit (Dako). Primary antibody (human anti-mouse CD31, 
Dako; human anti-mouse α-smooth muscle actin, Abcam, Cambridge, MA; or 
human anti-mouse calponin, Abcam) was diluted 1:50 in TBS-T and incubated at 
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4°C overnight. Slides were then treated with HRP-conjugated anti-mouse 
secondary antibody provided in the kit. Hematoxylin and eosin counterstaining 
followed. Negative controls using secondary antibody alone were generated in 
parallel to ensure that non-specific staining did not occur.  
 
Immunofluorescent Staining 
For fluorescent staining, explanted tissue samples were initially incubated 
in 30% sucrose for 48 hours at 4°C.  They were then transferred to a solution 
containing 1 part OCT embedding compound (Andwin Scientific, Schaumburg, 
IL) and 2 parts 30% sucrose for another 24 hours.  Each sample was then finally 
embedded in 100% OCT within a disposable plastic mold (Fisher Scientific), and 
flash frozen on the surface of liquid nitrogen. These frozen samples were then 
forwarded to AML Laboratories for cryosectioning in 5 μm sections. Frozen 
sections returned to our laboratory were pre-warmed for 20 minutes at 25°C. 
Slides were submerged in PBS pH 7.4 for 3 separate 5 minute washes, then 
blocked using 5% goat serum in PBS to eliminate non-specific protein binding. 
Primary antibody (anti-rabbit human CD31, Santa Cruz Biotechnologies, Santa 
Cruz, CA) was diluted 1:50 in 5% goat serum and incubated at 4°C overnight. 
After incubation, unbound antibody was removed with 3 washes of 5 minutes 
each with PBS. Secondary antibody (AlexaFluor-488 goat anti-rabbit, Invitrogen) 
at a 1:100 concentration was incubated for 30 minutes at room temperature. 
Unbound antibody was removed with 3 washes of 5 minutes each with PBS. 
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Slides were then covered with VectaShield (Vector Labs, Burlingame, CA) and a 
#1 glass coverslip. 
 
Design of an image analysis program for quantification 
A customized MATLAB algorithm was described previously (32). Briefly, 
images of the green channel (AlexaFluor 488-hCD31) were used to determine 
the location of capillaries, either in longitudinal or cross sections on each section. 
The red channel (Texas Red-dextran) was then overlayed and the percentages 
of its localization, either within the capillaries, or external to the capillaries, were 
determined. 
 
Quantification of Average Number of Vessels per Field of View 
Using hCD31 stained slides, the number of blood vessels derived from 
implanted cells were quantified manually. Blood vessels were identified if they 
exhibited a rim of positive hCD31 stain and a hollow lumen containing 
erythrocytes. Three sections, with 5 randomly taken images per section at 20x, 
were used to achieve statistical significance. All values were normalized to 
represent one mm2 area. 
 
Statistical Analysis 
All statistical analyses were performed using GraphPad Prism (GraphPad 
Software, La Jolla, California). Data are reported as mean ± standard deviation. 
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Two-way analysis of variance was performed with a Newman-Keuls multiple 
comparison post-test. Statistical significance was assumed when p < 0.05.  
5.3 Results 
A. Co-Injection of ECs with Supporting Stromal Cells Restored Perfusion 
 In this study, ECs alone or in combination with one of three different types 
of stromal cells (NHLFs, AdSCs, or MSCs) were injected subcutaneously within a 
fibrin matrix on the dorsal surface of SCID mice as depicted schematically in 
Figure 5.1.  Laser Doppler perfusion imaging (LDPI) was used to non-invasively 
quantify blood perfusion after subcutaneous injection of one of 5 treatment 
groups. LDPI was first performed on all mice prior to implantation in order to 
provide a baseline control value of dorsal vascular perfusion. It was then 
performed again on days 3, 7, 10, and 14 post-implantation.  As shown in Figure 
5.2, relative perfusion values increased over the course of the experiment for  
 
 
 
 
Figure 5.2. Subcutaneous co-injection of EC and supporting stromal cells within fibrin matrices restore 
perfusion better than delivery of EC alone.  Laser Doppler perfusion imaging was used to non-invasively 
quantify blood perfusion after subcutaneous injection of one of 5 treatment groups (all within fibrin gels): 
EC, EC-AdSC, EC-MSC, EC-NHLF, or fibrin alone. Co-delivery of EC with AdSC, MSC, or NHLF within 
a fibrin matrix successfully restored blood flow to pre-injection levels (control). Delivery of EC alone 
partially restored blood flow by 7 days, but perfusion dropped off as the unstable vasculature was 
pruned. Acellular fibrin gels failed to restore perfusion to pre-injection levels within 14 days. Statistical 
comparisons are denoted on the graph by letters. a, b, c, and d denote statistically significant differences 
(p < 0.05) within each experimental group (i.e., a is significantly different than b, c, and d, etc.). e, and f 
indicate statistically significant differences (p < 0.05) across the different experimental groups (i.e., e is 
significantly different than f).   
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treatment groups; however, key differences were seen among different 
conditions. Co-delivery of ECs with AdSCs, MSCs, or NHLFs within a fibrin 
matrix successfully restored blood flow to pre-injection levels within 7 days.  The 
restored level of perfusion was maintained at 14 days for these multicellular 
implants.  By comparison, delivery of ECs alone partially restored blood flow by 7 
days, but perfusion dropped off in the subsequent 7 days. Acellular fibrin gels 
failed to restore perfusion to pre-injection levels within 14 days. 
 
B. Live Implant Imaging Qualitatively Confirmed Perfusion of the Neovasculature 
 Immediately after implant removal, whole-mount live imaging was 
performed, revealing some qualitative, yet striking, differences in the appearance 
of the explanted tissues (Figure 5.3). At day 7, all of the retrieved implants were 
red, perhaps indicative of connecting to the host vasculature, although the 
implant from the EC-NHLF condition was notably the most red (Figure 5.3A).  
The visible redness suggests erythrocyte leakage into the implant. After 14 days 
(Figure 5.3B), the bright red color remained present in the EC alone and EC-
NHLF conditions; by contrast, the red color diminished in the EC-AdSC and EC-
MSC implants.  Implants for these latter two conditions were a pale pink/yellow 
color in macroscopic appearance by day 14, yet retained easily identifiable blood 
vessels that were bright red in color.  At this later time point, the fibrin also 
appeared somewhat more compacted and perhaps more degraded in the EC 
alone and EC-NHLF conditions. 
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Figure 5.3. Whole-mount live imaging shows perfusion of implant neovessels. Explants of each 
treatment group imaged as live whole-mounts at (A) day 7 and (B) day 14. Insets are macroscopic 
photographs. Implants show varying degrees of effective perfusion and edema, dependent on implanted 
cell types. By day 14, EC only and EC-NHLF groups are visibly more red than the EC-AdSC and EC-
MSC groups, suggesting large amounts of free erythrocytes.  Thus, while all treatment groups are 
perfused, the quality of the neovasculature is highly dependent on the identity of the stromal cells.  
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C. Stromal Cells of Different Origins Produced Vessels with Distinct 
Morphologies 
 
 Images of the H&E-stained day 7 and 14 explants revealed additional 
qualitative differences in the morphologies of the vessels formed in the various 
experimental groups (Figure 5.4). Stained sections from the day 7 EC-only 
implants contained many large vessel-like structures, but these structures lacked 
a consistent, circumscribed geometry and the implants contained obvious 
extravascular erythrocytes (Figure 5.4A). Significant vessel regression and matrix 
degradation was apparent by day 14 (Figure 5.4B). The cells that remained in the 
fibrin by day 14 were mainly spindle-shaped free ECs, and there was little 
evidence of organization into capillary structures. EC-NHLF implants also 
contained many immature, interconnected blood vessels at day 7 (Figure 5.4A), 
but it was difficult to discern clear vessel boundaries due to the somewhat 
chaotic and irregular shapes of the vessel-like structures and large amounts of 
matrix reorganization. After 14 days, there appeared to be a qualitative decrease 
in the amount of free erythrocytes in the explanted EC-NHLF tissues, but some 
still remained. By contrast, implants containing the multipotent stromal cells 
(AdSC or MSC) yielded starkly different results.  These samples contained many 
small capillaries with very well-defined lumens, circumscribed borders, and very 
few free erythrocytes. These capillaries were distributed throughout the entire 
implant to produce a vascularized, homogeneous implant containing both large 
and small blood vessels throughout in order to effectively supply the tissue with 
oxygenated blood.   
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Figure 5.4. Histological staining illustrates varying blood vessel morphologies in implants across 
treatment groups. Histologically stained sections of implants retrieved at (A) day 7 or (B) day 14 post 
injection. Nascent vessel morphology varies based on the presence or absence of implanted stromal 
cells, and the type of stromal cell included.  Consistent with the whole mount images (Figure 3), the EC 
only and EC-NHLF groups show vasculature that is much less defined than the EC-AdSC and EC-MSC 
groups, particularly at day 7.   
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 Immunohistochemical staining for human CD31 validated the observations 
from the H&E-stained sections, and confirmed the human origins of the 
neovasculature (Figure 5.5). In the implants containing ECs only, there was a 
diffuse brown stain indicating an abundance of human ECs and some lumen-like 
structures, especially at day 7 (Figure 5.5A). The EC-NHLF implants showed 
many elongated vessel-like structures. By contrast, the EC-MSC and EC-AdSC 
implants contained many smaller, tightly-sealed capillaries, consistent with the 
observations from H&E staining. Quantification of vascular density from these 
types of images supported these qualitative observations (Figure 5.5C). 
Specifically, EC only implants contained 46 ± 3 vessels per mm2 at 7 days, but 
this value dropped to 9 ± 2 vessels per mm2 by day 14. EC-NHLF implants 
contained 47 ± 6 vessels per mm2 at day 7, which was reduced to 31 ± 2 vessels 
per mm2 by day 14. Relative to these two conditions, the EC-AdSC and EC-MSC 
implants produced fewer numbers of blood vessels. EC-AdSC implants 
contained 29 ± 7 and 19 ± 4 vessels per mm2 at days 7 and 14 respectively.  EC-
MSC implants formed 20 ± 4 and 13 ± 3 vessels per mm2 at days 7 and 14, 
respectively.  Acellular fibrin implants showed little evidence of vascularization or 
host network invasion (see Supplementary Figure S5.1). By 14 days post-
implantation, the fibrin implants had been resorbed by the host, and normal host 
dorsal vasculature was observed at the implantation site.  
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Figure 5.5. Human CD31 staining confirms blood vessel origin. hCD31 staining of implants at either (A) 
day 7 or (B) day 14 post implantation shows that the nascent vasculature arises due in part to the 
transplanted human cells (as opposed to due to host vessel infiltration). All samples have been 
counterstained with H&E. (C) Quantification of images from (A) and (B). In the graph, “a” denotes 
statistically significant differences (p < 0.05) across time points within each experimental group. B, c, d, 
e, f, and g indicate statistically significant differences (p < 0.05) across different experimental groups (i.e. 
b is statistically different than c, d, e, f, and g, etc.). 
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D. Stromal Cells with Multilineage Potential Express Markers of Mature Smooth 
Muscle 
 
 
 One possible explanation for the observed differences in vessel morphology 
is that the multipotent stromal cells may possess the ability to differentiate into 
pericytes, or even mature smooth muscle cells, while the fibroblasts cannot.  To 
assess this possibility in our experimental system, we stained histological 
sections for two different markers – alpha-smooth muscle actin (α-SMA) and 
calponin (Figure 5.6). α -SMA has been widely used as a pericyte marker(18), 
while calponin is a marker of mature smooth muscle (34).  IHC staining of human 
α-SMA revealed a broadly positive result for all of the implants containing a co-
delivered stromal cell type, particularly at day 7 (Figure 5.6A). By day 14, this 
positive staining had somewhat decreased across all multicellular implants. In the 
EC-MSC and EC-AdSC implants, positive α-SMA staining was circumferentially 
localized around the newly developed blood vessels, while the EC-NHLF 
implants contained a more diffuse positive staining of cells throughout the matrix.  
By contrast, calponin staining was only positive at day 14 in the implants 
containing AdSC or MSC (Figure 7, particularly panel B). These results suggest 
that, while NHLFs, AdSCs, and MSCs are all capable of promoting the formation 
of vasculature and expressing α-SMA, only the multipotent AdSCs and MSCs are 
capable of differentiating into a mature smooth muscle phenotype that is the 
hallmark of a larger and more mature vasculature. 
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Figure 5.6-SMA staining identifies stromal cells within the implant. Human alpha smooth muscle actin 
staining at (A) 7 days and (B) 14 days post implantation. Broad positive staining is observed in in EC-
NHLF, EC-AdSC, and EC-MSC groups at day 7. Expression levels are somewhat modulated by day 14, 
suggesting a transition from a myofibroblast phenotype to more mature pericytes.  
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Figure 5.7. Calponin staining identifies mature smooth muscle cells within the implant. Calponin staining 
at (A) 7 days and (B) 14 days post implantation. No positive staining is observed at day 7 for any of the 
conditions. By day 14, positive staining (indicated by white arrows) is found in the EC-AdSC and EC-
MSC groups, suggesting the co-implanted stromal cells differentiate towards a more mature smooth-
muscle-like phenotype over time.  The NHLFs do not differentiate in this same manner.  
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E. Stromal Cell Presence and Identity Alter the Functional Permeability of the 
Neovessels 
 
 The data presented thus far suggest that all 3 stromal cell types – NHLFs, 
AdSCs, and MSCs – are capable of promoting the formation of vasculature in 
subcutaneous pockets when co-delivered with ECs.  The histological findings hint 
at possible functional differences in the neovessels that form, but nearly all of the 
observed differences have been qualitative, subjective, and frankly unsatisfying.  
Therefore, in the final part of this study, we sought to determine how the inclusion 
of the stromal cells and their various identities quantitatively affect the functional 
properties of engineered capillary networks.   
 Based on some recent in vitro findings, we hypothesized that the resistance 
to permeability of the nascent vessels would strongly depend on stromal cell 
identity (32). To quantify the relative permeabilities of the vasculature formed in 
vivo, a 70 kDa fluorescent dextran molecule was injected via tail vein in the 
various experimental animals. (Systemic injection of the functionally-defining 
tracer can be seen at the host-implant interface in Supplementary Figure S5.2.)  
Inclusion of either AdSCs or MSCs in the implants resulted in much tighter 
control of permeability relative to the other conditions (Figure 8). In the EC only 
and EC-NHLF groups, a significant fraction of the fluorescent dextran was 
observed outside of the vessel borders (defined by the green CD31 staining), 
and freely diffused throughout the implant tissue (Figure 5.8A). By comparison, 
EC-AdSC and EC-MSC groups contained very well-defined vessels in which the 
Texas Red-dextran was circumscribed by human-CD31+ cells, with significantly 
less red signal in the surroundings. Importantly, we had also previously 
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developed and validated an automated, MATLAB-based image-processing 
algorithm to quantify vessel permeability (32). When we applied this algorithm to 
quantify the relative fluorescence contained with lumens as described in the 
Materials and Methods, the resulting data confirmed that co-delivery of ECs with 
AdSCs or MSCs yields vessels whose control of permeability is superior (Figure  
5.8B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8. Co-injection of EC with AdSC or MSC
yields neovasculature with superior functional
properties. (A) SCID mice were subjected to tail vein
injections of 70 kDa Texas Red-dextran (red) tracer to
visualize inosculation and characterize vessel
leakiness.  Tissues were counter-stained with anti-
human CD31 antibodies (green) to verify the human
origins of the vessels. In the EC only and EC-NHLF
groups, a significant fraction of the Texas Red-dextran
is observed outside of the vessel borders (defined by
the green CD31 staining). By comparison, EC-AdSC
and EC-MSC groups contained very well-defined
vessels in which the TRITC-dextran is circumscribed by
human-CD31+ cells, with significantly less red signal in
the surrounding tissue. (B) Quantitative data confirm
that co-delivery of EC with AdSC or MSC yields
vessels whose control of permeability is superior. In the
graph, “a” indicates statistical significance (p<0.05)
across time points within a single group. Across
groups, each “b” is significantly different from all other
“b’s”, and each “c” is significantly different from all other
“c’s”.
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5.4 Discussion 
 
 This study examined the quantity and functional quality of engineered 
capillary networks formed via co-delivery of ECs with one of three types of 
supporting stromal cells (NHLF, MSC, or AdSC) in a fibrin-based implant. We 
focused our efforts on these three stromal cell types not only because of our own 
prior in vitro work (24, 31, 32), which has suggested some differences in the 
mechanisms by which these cells promote vascularization, but also because their 
use has been gaining traction in the tissue engineering literature in recent years.  
In the case of fibroblasts, their co-delivery with stem cell-derived cardiomyocytes 
and ECs has been explored in the context of vascularized cardiac patches (35). 
A high density of co-transplanted NHLFs in particular in a prevascularized tissue 
construct was recently shown to accelerate the rate of inosculation between host 
vessels and the implanted vessels (28).  Likewise, AdSCs co-delivered with ECs 
in collagen-based implants have been shown to enhance vascularization, and to 
help sustain pancreatic islets or adipocytes (36).  There are also a number of 
studies that have explored the utility of MSCs co-delivered with ECs to build 
functional vasculature (22, 25).   
 The results presented here show that all four of the experimental groups 
(EC alone, EC-NHLF, EC-AdSC, and EC-MSC) yielded new human-derived 
vessels that inosculated with mouse vasculature and perfused the implant with 
blood.  However, functional differences in the capillary networks were also 
revealed, depending on the identity of the co-delivered stromal cells.  Importantly, 
the observed differences in vessel function were not apparent in data generated 
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by manually counting numbers of vessels in H&E or hCD31-stained histological 
sections, the most common endpoint utilized to assess functional connections 
between implanted capillary beds and the host vasculature.   
 Laser Doppler perfusion imaging (LDPI) was also used to assess blood 
flow, and thus provide an indirect indication of inosculation between the host 
vessels and the newly developed vasculature within the implant. This method 
has been widely employed in the tissue engineering literature to assess the 
success of revascularization therapies (37, 38).  The main advantages of this 
technology are its non-invasive and real-time measuring capabilities. In our 
study, mice were anesthetized for a short period and experiments performed 
longitudinally across multiple time points with the same mouse.  However, LDPI 
results may be somewhat misleading, as the data in Figure 5.2 suggest.  
Specifically, we found that co-delivery of EC with AdSC, MSC, or NHLF within a 
fibrin matrix successfully restored blood flow to pre-injection levels, with no 
significant differences between them. Delivery of EC alone partially restored 
blood flow by 7 days, but perfusion dropped off as the unstable vasculature was 
pruned. From these data alone, one might conclude that AdSC, MSC, and NHLF 
are all equal with respect to their ability to promote functional vessels that can 
perfuse an implant.  However, erythrocyte pooling and edema into the implants 
could not be quantified via LDPI.  
 Macroscopic images (Figure 5.3) suggested some differences across the 
different experimental groups. EC-NHLF implants were visibly red to the naked 
eye, especially at the day 7 time point. EC-MSC and EC-AdSC implants were 
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significantly lighter in color by comparison. Implants containing only ECs were 
somewhere in between in gross appearance. H&E staining of the retrieved 
implants (Figure 5.4) revealed many free erythrocytes within the EC-only and 
EC-NHLF implants.  The presence of multipotent stromal cells, either from bone 
marrow or adipose, yielded smaller, more well-defined blood vessels throughout 
the implants. These vessels appeared to be tightly lined with ECs, as identified 
by the hCD31 staining (Figure 5.5A-B). However, manual quantification of 
perfused lumen-containing structures on these hCD31-stained sections (Figure 
5.5C) seemed to suggest that EC-NHLF co-delivery was superior to EC-MSC or 
EC-AdSC co-delivery in terms of numbers of vessels. Implants containing ECs 
alone also appeared to yield greater numbers of vessels initially, but these 
vessels were unstable in the absence of a co-delivered stromal cell.  In fact, it 
was only when we assessed the permeability of the engineered vessel networks 
by systemically injecting a fluorescent tracer into the host circulation that the 
functional superiority of co-delivering ECs with the multipotent stromal cells 
emerged. As shown in Figure 5.8, a significant fraction of the Texas Red-dextran 
leaked outside of the vessel borders in the EC only and EC-NHLF groups, 
especially at the day 7 time point.  By comparison, the fluorescent dextran was 
better retained with the vessels in the EC-AdSC and EC-MSC groups.   
 One possible explanation for the superior functional properties of the 
vessels created in the EC-AdSC and EC-MSC groups is the fact that the 
multipotent AdSCs and MSCs are capable of differentiating into pericytes, and 
perhaps even functional smooth muscle, while the NHLFs are not.  However, 
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assessing this possibility is difficult due to the limited availability of bona fide 
pericyte markers.  Smooth muscle α-actin is commonly used as a pericyte 
marker (39, 40), but it is also a marker of myofibroblasts (41).  In our results, the 
EC only condition is negative for α-SMA, but all of the other conditions show 
some degree of positive staining (Figure 5.6). The EC-NHLF implants show 
several small, stippled areas of positive staining. By contrast, only the EC-AdSC 
and EC-MSC implants show positive calponin staining, an indication of possible 
smooth muscle differentiation, and only after 14 days (Figure 5.7), implying 
evolvement of a smooth muscle-like phenotype of implanted stromal cells. 
Together, these two pieces of data suggest that the AdSCs and MSCs may be 
able to differentiate into functional pericytes, and eventually smooth muscle cells, 
and thus are much better able to stabilize the new vessel networks and modulate 
their permeability.  By contrast, the terminally differentiated NHLFs (and perhaps 
fibroblasts more generally) act more as myofibroblasts in a wound-healing 
environment, rapidly promoting vessel formation in order to heal the wound.  
Prior results from an in vitro comparison of these different stromal cell types 
show that NHLFs promote capillary morphogenesis at a faster rate (32), 
consistent with this possible explanation.  
 In conclusion, the results of this study suggest that the identity of the 
stromal cells co-delivered with ECs is key to controlling the functional properties 
of vasculature engineered via cell delivery, and argue that multipotent stromal 
cells with the ability to differentiate in situ are superior to terminally-differentiated 
fibroblasts.  Importantly, this study also underscores the need for more 
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quantifiable metrics of functionality, rather than relying solely on the manual 
counting of the numbers of vessels in histological sections. 
5.5 References 
 
1. Ferrara N, and Alitalo K. Clinical applications of angiogenic growth factors 
and their inhibitors. Nat Med 5, 1359-1364 (1999). 
2. Davis BH, Schroeder T, Yarmolenko PS, Guilak F, Dewhirst MW, and 
Taylor DA. An in vitro system to evaluate the effects of ischemia on 
survival of cells used for cell therapy. Ann Biomed Eng 35, 1414-1424 
(2007). 
3. Chen RR, Silva EA, Yuen WW, Brock AA, Fischbach C, Lin AS, Guldberg 
RE, and Mooney DJ. Integrated approach to designing growth factor 
delivery systems. Faseb J (2007). 
4. Sun Q, Silva EA, Wang A, Fritton JC, Mooney DJ, Schaffler MB, 
Grossman PM, and Rajagopalan S. Sustained release of multiple growth 
factors from injectable polymeric system as a novel therapeutic approach 
towards angiogenesis. Pharm Res 27, 264-271 (2010). 
5. Lee KY, Peters MC, Anderson KW, and Mooney DJ. Controlled growth 
factor release from synthetic extracellular matrices. Nature 408, 998-1000 
(2000). 
6. Murphy WL, and Mooney DJ. Controlled delivery of inductive proteins, 
plasmid DNA and cells from tissue engineering matrices. J Periodontal 
Res 34, 413-419 (1999). 
142 
7. Sun Q, Chen RR, Shen Y, Mooney DJ, Rajagopalan S, and Grossman 
PM. Sustained vascular endothelial growth factor delivery enhances 
angiogenesis and perfusion in ischemic hind limb. Pharm Res 22, 1110-
1116 (2005). 
8. Zisch AH, Lutolf MP, Ehrbar M, Raeber GP, Rizzi SC, Davies N, 
Schmokel H, Bezuidenhout D, Djonov V, Zilla P, and Hubbell JA. Cell-
demanded release of VEGF from synthetic, biointeractive cell ingrowth 
matrices for vascularized tissue growth. Faseb J 17, 2260-2262 (2003). 
9. Richardson TP, Peters MC, Ennett AB, and Mooney DJ. Polymeric system 
for dual growth factor delivery. Nat Biotechnol 19, 1029-1034 (2001). 
10. Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, Mori Y, Kojima H, 
and Iwasaka T. Angiogenesis by implantation of peripheral blood 
mononuclear cells and platelets into ischemic limbs. Circulation 106, 
2019-2025 (2002). 
11. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, and 
Epstein SE. Local delivery of marrow-derived stromal cells augments 
collateral perfusion through paracrine mechanisms. Circulation 109, 1543-
1549 (2004). 
12. Pesce M, Orlandi A, Iachininoto MG, Straino S, Torella AR, Rizzuti V, 
Pompilio G, Bonanno G, Scambia G, and Capogrossi MC. Myoendothelial 
differentiation of human umbilical cord blood-derived stem cells in 
ischemic limb tissues. Circ Res 93, e51-62 (2003). 
143 
13. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, 
Bovenkerk JE, Pell CL, Johnstone BH, Considine RV, and March KL. 
Secretion of angiogenic and antiapoptotic factors by human adipose 
stromal cells. Circulation 109, 1292-1298 (2004). 
14. Nor JE, Christensen J, Mooney DJ, and Polverini PJ. Vascular endothelial 
growth factor (VEGF)-mediated angiogenesis is associated with enhanced 
endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 
154, 375-384 (1999). 
15. Nor JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK, 
Addison CL, Mooney DJ, and Polverini PJ. Engineering and 
characterization of functional human microvessels in immunodeficient 
mice. Lab Invest 81, 453-463 (2001). 
16. Baluk P, Hashizume H, and McDonald D. Cellular abnormalities of blood 
vessels as targets in cancer. Current Opinion in Genetics & Development 
15, 102-111 (2005). 
17. Carmeliet P, and Jain R. Angiogenesis in cancer and other diseases. 
Nature 407, 249-257 (2000). 
18. Jain RK, Au P, Tam J, Duda DG, and Fukumura D. Engineering 
vascularized tissue. Nat Biotechnol 23, 821-823 (2005). 
19. Melero-Martin J, Obaldia MD, Kang S, Khan Z, Yuan L, Oettgen P, and 
Bischoff J. Engineering robust and functional vascular networks in vivo 
with human adult and cord blood-derived progenitor cells. Integrative 
Physiology 103, 194-202 (2008). 
144 
20. Hashizume H, Baluk P, Morikawa S, McLean J, Thurston G, Roberge S, 
Jain R, and McDonald D. Openings between defective endothelial cells 
explain tumor vessel leakiness. American Journal of Pathology 156, 1363-
1380 (2000). 
21. Ghajar CM, Blevins KS, Hughes CC, George SC, and Putnam AJ. 
Mesenchymal stem cells enhance angiogenesis in mechanically viable 
prevascularized tissues via early matrix metalloproteinase upregulation. 
Tissue Eng 12, 2875-2888 (2006). 
22. Kniazeva E, Kachgal S, and Putnam AJ. Effects of extracellular matrix 
density and mesenchymal stem cells on neovascularization in vivo. Tissue 
Eng Part A 17, 905-914 (2011). 
23. Bergers G, and Song S. The role of pericytes in blood-vessel formation 
and maintenance. Neuro-Oncology 7, 452-464 (2005). 
24. Ghajar CM, Kachgal S, Kniazeva E, Mori H, Costes SV, George SC, and 
Putnam AJ. Mesenchymal cells stimulate capillary morphogenesis via 
distinct proteolytic mechanisms. Exp Cell Res 316, 813-825 (2010). 
25. Au P, Tam J, Fukumura D, and Jain RK. Bone marrow-derived 
mesenchymal stem cells facilitate engineering of long-lasting functional 
vasculature. Blood 111, 4551-4558 (2008). 
26. Merfeld-Clauss S, Gollahalli N, March K, and Traktuev D. Adipose tissue 
progenitor cells directly interact with endothelial cells to induce vascular 
network formation. Tissue Engineering Part A 16, 2953-2966 (2010). 
145 
27. Ghajar CM, Chen X, Harris JW, Suresh V, Hughes CC, Jeon NL, Putnam 
AJ, and George SC. The effect of matrix density on the regulation of 3-D 
capillary morphogenesis. Biophys J 94, 1930-1941 (2008). 
28. Chen X, Aledia AS, Popson SA, Him L, Hughes CC, and George SC. 
Rapid anastomosis of endothelial progenitor cell-derived vessels with host 
vasculature is promoted by a high density of cotransplanted fibroblasts. 
Tissue Eng Part A 16, 585-594 (2010). 
29. Motegi S, Leitner W, Lu M, Tada Y, Sardy M, Wu C, Chavakis T, and 
Udey M. Pericyte-derived MFG-E8 regulates pathologic angiogenesis. 
Arteriosclerosis, thrombosis, and vascular biology 31, 2024-2034 (2011). 
30. Shepherd BR, Jay SM, Saltzman WM, Tellides G, and Pober JS. Human 
aortic smooth muscle cells promote arteriole formation by coengrafted 
endothelial cells. Tissue Eng Part A 15, 165 (2009). 
31. Kachgal S, and Putnam AJ. Mesenchymal stem cells from adipose and 
bone marrow promote angiogenesis via distinct cytokine and protease 
expression mechanisms. Angiogenesis 14, 47-59 (2011). 
32. Grainger SJ, and Putnam AJ. Assessing the permeability of engineered 
capillary networks in a 3D culture. PLoS One 6, e22086 (2011). 
33. Curry FE, Huxley VH, and Adamson RH. Permeability of single capillaries 
to intermediate-sized colored solutes. Am J Physiol 245, H495-505 (1983). 
34. Hughes S, and Chan-Ling T. Characterization of smooth muscle cell and 
pericyte differentiation in the rat retina in vivo. Investigative Ophthalmology 
& Visual Science 45, 2795-2806 (2004). 
146 
35. Stevens KR, Kreutziger KL, Dupras SK, Korte FS, Regnier M, Muskheli V, 
Nourse MB, Bendixen K, Reinecke H, and Murry CE. Physiological 
function and transplantation of scaffold-free and vascularized human 
cardiac muscle tissue. Proc Natl Acad Sci U S A 106, 16568-16573 
(2009). 
36. Traktuev DO, Prater DN, Merfeld-Clauss S, Sanjeevaiah AR, 
Saadatzadeh MR, Murphy M, Johnstone BH, Ingram DA, and March KL. 
Robust functional vascular network formation in vivo by cooperation of 
adipose progenitor and endothelial cells. Circulation Research 104, 1410-
1420 (2009). 
37. Phelps EA, Landazuri N, Thule PM, Taylor WR, and Garcia AJ. 
Bioartificial matrices for therapeutic vascularization. Proc Natl Acad Sci U 
S A 107, 3323-3328 (2010). 
38. Silva EA, Kim ES, Kong HJ, and Mooney DJ. Material-based deployment 
enhances efficacy of endothelial progenitor cells. Proc Natl Acad Sci U S 
A 105, 14347-14352 (2008). 
39. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, 
Scheding S, and Bengzon J. Bone marrow multipotent mesenchymal 
stroma cells act as pericyte-like migratory vehicles in experimental 
gliomas. Molecular Therapy 17, 183-190 (2008). 
40. Shi S, and Gronthos S. Perivascular niche of postnatal mesenchymal 
stem cells in human bone marrow and dental pulp. Journal of Bone and 
Mineral Research 18, 696-704 (2003). 
147 
41. Hinz B. Formation and function of the myofibroblast during tissue repair. 
Journal of Investigative Dermatology 127, 526-537 (2007). 
42. Schechner JS, Nath AK, Zheng L, Kluger MS, Hughes CC, Sierra-
Honigmann MR, Lorber MI, Tellides G, Kashgarian M, Bothwell AL, and 
Pober JS. In vivo formation of complex microvessels lined by human 
endothelial cells in an immunodeficient mouse. Proc Natl Acad Sci U S A 
97, 9191-9196 (2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
148 
Supplementary Information 
Methods: 
Transduction of Cells for Live Imaging 
HUVECs were transduced with monomeric green fluorescent protein (GFP) using 
the Phoenix Retrovirus Expression System (Orbigen, San Diego, CA). The 
pBMN-GFP vector was obtained commercially and cells were transduced as 
described elsewhere.(22) Viral transductions were performed for a 6 hour period 
daily for a total of 4 days.  
Figures: 
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Figure S5.1. Acellular control implants 
show no evidence of neovascularization. 
Acellular implants show no evidence of 
new blood vessel formation either via 
H&E or anti-hCD31 staining. By day 14, 
fibrin implants have mostly resorbed. 
Figure S5.2. Systemic injection allows 
imaging of host-implant interface. 
Systemically injected Texas Red-dextran 
(70kDa) approaches the interface between 
GFP-hECs in the implant and the host blood 
vessels that are inosculating with the implant.  
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CHAPTER 6 
Conclusions & Future Directions 
 
6.1 CONCLUSIONS 
 The main conclusion of this thesis is that stromal cell identity has direct 
implications on the control of permeability and function of developing capillary 
networks. This conclusion was reached from several angles. First, three 
dimensional in vitro studies showed that capillaries with different stromal cell 
components have different morphologies, grow and mature at different rates, and 
have different ultimate permeability capabilities. Next, some of the mechanistic 
components of the differentiation of stromal cells into pericytes were examined 
via western blotting and immunofluorescent staining for proteins such as vascular 
endothelial cadherin, alpha smooth muscle actin, and calponin. Finally, these 
results were verified in an in vivo model of subcutaneous wound healing. Live 
imaging of the implants, quantification of blood flow through the implant 
neovasculature, histology and immunohistochemical staining, and permeability 
tracer studies allowed for evaluation of the blood vessels produced in implants 
with each of the different stromal cells studied here. In short, vessels produced 
from co-implants of MSCs or AdSCs with ECs produced capillaries that were 
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much more able to control permeability and produce capillaries similar to those of 
a physiologically healthy nature, over EC alone or EC-fibroblast cultures.  
First, an in vitro imaging modality and quantification assay were 
developed, tested, and then translated into an in vivo application of 
subcutaneous wound healing. Early work used an established method of growing 
capillaries in vitro to develop an inverse permeability assay for use in evaluating 
differences across stromal cell types. Thickness testing showed that thin gels 
were required in order to allow imaging through bulk gel with a freely diffusible 
tracer. VE-cadherin staining in 3D allowed for imaging of newly developing cell-
cell junctions between endothelial cells. This imaging modality also proved to be 
difficult in terms of effective definition of developing capillary boundaries. 
Because of this, HUVECs were tagged with GFP to allow for live cell imaging, or 
CD31 staining was used to define capillary borders in the assay after fixation. 
Dextran diffusion throughout the bulk gels posed an initial challenge as 
described; however, fixation of the cultures to attach the dextran to the fibrin 
matrices assisted in visualization of the dextran localization in the cultures.  
 The assay was challenged with a known modulator of permeability on 
capillaries, histamine. This resulted in across the board increases in permeability, 
regardless of the number of days in culture or maturation level of the capillary 
cultures. Regardless of treatment with histamine, three distinct phases of 
capillary maturation were seen across the two-week cultures. Initially, a phase of 
sprouting is seen, with few cell-cell junctions between the endothelial cells, and 
little control over permeability. Much tracer is able to accumulate within the 
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capillary sprout lumens. Next, a mid-phase is observed, where VE-cadherins 
junctions are beginning to develop, and permeability levels decrease. Finally, a 
phase of maturation is observed, with tight control over permeability and well-
defined cell-cell junctions.  
Once the model was well established, differences in capillary phenotype 
and permeability control across stromal cell types were compared. In 3D co-
culture with ECs, as well as monoculture, MSCs promote higher levels of VE-
cadherin expression over the use of NHLFs or AdSCs, implying a mechanism of 
stabilization is occurring with MSCs, and potentially with AdSCs, to a lesser 
degree. The stem cells may be capable of modulating their phenotype to induce 
capillary maturation, while still maintaining a stromal cell phenotype. Also 
Capillaries with stem cells included in the co-cultures also resulted in much more 
highly branched constructs than those with fibroblasts. Fibroblasts promoted 
more of a wound healing environment, with longer, spindly capillaries and less 
control over permeability than the stem cell co-cultures. We hypothesized that 
the stem cells are able to differentiate into more of a pericytic phenotype than the 
fibroblasts, thus resulting in tighter permeability control and effective stabilization 
of the capillaries. 
Next, the model was adapted for an in vivo setting. All co-implants showed 
achievement of normal perfusion levels; however, upon further investigation, 
phenotypic and functional differences were seen between each of the treatment 
groups. Live whole-mount and macroscopic imaging revealed large amounts of 
erythrocyte pooling in the EC-fibroblast co-cultures, even at long time points. A 
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similar trend was seen in the EC alone group, although these vessels started to 
regress by 14 days post-implantation due to a lack of stromal cell stabilization. 
Histology confirmed these results, and also revealed many interconnected, 
immature blood vessels, as well as the development of granulation tissue in the 
EC-fibroblast implants. The EC-stem cell implants showed more mature, 
developed blood vessels, and less erythrocyte pooling than the EC-fibroblast 
group.  
Further exploration into the pericytic differentiation mechanism of each of 
the stromal cell types yielded interesting results as well. Western blotting for both 
α-SMA, a myofibroblast and accepted pericytic marker, and calponin, a smooth 
muscle marker, was done on both 2D and 3D in vitro cultures. Positive results for 
α-SMA were seen across the board in 2D, and in 3D for EC-NHLF co-cultures, 
but not for cultures containing MSCs and AdSCs. When ECs were included in the 
co-cultures, MSCs and AdSCs downregulated expression of α-SMA. This result 
implies a modulation away from a myofibroblastic phenotype in 3D culture for 
MSCs, and suggests the need for a more definitive marker of capillary pericytes. 
In vivo, positive α-SMA staining was seen for all three stromal cell groups at early 
time points, but modulated by day 14 in the stem cell groups. In these groups, 
staining was only present at the periphery of each newly developed blood vessel, 
implying a pericytic phenotype in the stem cell co-implants. Because the cells are 
positive for α-SMA in 2D culture, this suggests a myofibroblastic phenotype upon 
implantation, which is modulated in vivo to produce stabilized capillaries.  
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Along a similar vein, cells are not given the cues in vitro to differentiate 
into smooth muscle cells, resulting in a negative Western blot for calponin, even 
after long culture times. Staining of calponin within in vivo implants produced 
positive staining only at the longest time points, and only within the stem cell 
implants, surrounding the larger developing vessels. This result proves that the 
fibroblasts are not able to differentiate into true smooth muscle cells, as are 
needed for large vessel development and stabilization in an in vivo setting. 
Collectively, these results imply that the stem cell co-implants are able to 
produce stabilized, morphologically mature vessels with a hierarchical 
architecture, unlike the EC-fibroblast implants.  
Supporting these phenotypic results, similar permeability trends to those 
seen in vitro were observed across all time points and stromal cell conditions. 
EC-stem cell co-cultures were able to much more tightly control permeability after 
two weeks than those containing fibroblasts, effectively keeping tracer within the 
defined limits of the vasculature. Overall, the results of this thesis have 
conclusively shown that stromal cell identity is key to controlling permeability and 
effectively stabilizing developing vasculature. 
 
6.2 FUTURE DIRECTIONS 
 The results of this work indicate a mechanism for bringing tissue 
engineered vasculature to the clinic in a timely manner. Effective translation will 
require further characterization of the resulting blood vessels after injection of 
cells. Longer time points, further mechanistic characterization, and a platform of 
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induced ischemia should be tested in an in vivo setting prior to moving this work 
toward clinical applications. Another hurdle on the way to clinical translation is 
the use of autologous donor cells, rather than readily available, established cell 
sources. While this work was done with primary cells from human donors, this 
must be adapted to work in patients with normal immune responses, rather than 
only in SCID mice. Potential autologous donor cell types, such as endothelial 
progenitor cells, must be explored in these types of applications. Isolation and 
subsequent expansion into a useable volume for implantation must be further 
explored, as these are not trivial tasks. Also, effective isolation and expansion of 
adult stem cells from a patient must be further optimized if it is to be an option in 
the clinic. We must work to avoid blind implantation of stem cells in the hope that 
their healing power may be harnessed, as has been done in the past. Many other 
patient-to-patient variations in cellular behavior must be ironed out as well, to 
avoid complications and unanticipated outcomes in human patients. The effects 
of potentially existing illness on the donor patient cells must be characterized. 
Work to this point has been done on healthy patient donor cells, but has not yet 
been explored on cells donated from individuals with ischemic conditions. This 
may affect the numbers of circulating adult stem cells within the body, or have 
other implications that we have not anticipated at this point. 
 Further functional testing of the newly developed vessels must be done as 
well. The exact locations of pericytes, either in close proximity to, or in direct 
contact with, developing neovessels must be further explored. Effects of changes 
in integrin expression during sprout development, and after stabilization, must be 
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determined. The mechanism by which these stromal cells differentiate into 
pericytes and smooth muscle cells must ultimately be discovered. This would 
allow us to directly bypass the vessel development stages and directly treat 
ischemic diseases by their cause, instead of waiting to deal with the end effects.  
 We have hinted at the mechanistic results, seeing increased modulation of 
VE-cadherin and α-SMA expression with the use of stem cells over fibroblasts, 
and the inclusion of stromal cells over EC alone cultures; however, this is not 
enough. Further work into the differentiation of pericytes must be explored. If we 
could pre-direct these cells in vitro to decrease the time between implantation 
and anastamosis, this would produce direct, immediate results in the clinic, rather 
than waiting for implantation, sprouting, development, and stabilization (and 
pericytic differentiation) to occur. This could increase response time in the 
treatment of ischemic diseases, thus avoiding further complications and 
destabilization of the patient.  
